Novel compound and composition containing same as active ingredient for preventing, alleviating or treating bacterial inflammation and inflammasome-mediated diseases
By inhibiting quorum sensing and virulence factors of Gram-negative bacteria with a compound of chemical formula 1, and combining it with antibiotics, the treatment challenges of inflammatory diseases and neurodegenerative diseases caused by Gram-negative bacteria have been solved, achieving safer and more effective treatment results.
Patent Information
- Application Number
- CN202380023036.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-04
- Filing Date
- 2023-02-21
- Publication Date
- 2024-11-08
AI Technical Summary
Existing technologies are insufficient to effectively treat inflammatory diseases and neurodegenerative diseases caused by Gram-negative bacteria, and antibiotic use leads to drug resistance and toxicity problems.
To develop a novel therapeutic agent comprising a compound of Formula 1 and its isomers and a pharmaceutically acceptable salt, for inhibiting quorum sensing and virulence factors in Gram-negative bacteria, in combination with antibiotics to improve antibiotic sensitivity and reduce resistance.
It effectively inhibits the virulence of Gram-negative bacteria, reduces the toxicity of antibiotics, improves the effectiveness of antibiotics, and inhibits inflammasome-mediated diseases and neurodegenerative diseases.
Smart Images

Figure CN118922186A_ABST
Abstract
Description
Technical Field
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of Korean Patent Application No. 10-2022-0022320 filed on February 21, 2022, Korean Patent Application No. 10-2022-0140639 filed on October 27, 2022, Korean Patent Application No. 10-2022-0146145 filed on November 4, 2022, and Korean Patent Application No. 10-2023-0022804 filed on February 21, 2023, the disclosures of which are incorporated herein by reference in their entirety. Background Art
[0003] Gram-negative bacteria are known to cause periodontal disease, urinary tract infection, cystitis, pyelonephritis, abdominal infection, pneumonia, etc. They have high toxicity to the human body and therefore often lead to secondary infections such as nosocomial infection and opportunistic infection. If the bacteria of local infection are not properly controlled in the early stage, the toxicity of the bacteria will increase and eventually circulate in the blood, leading to a systemic inflammatory response (sepsis), which can lead to organ failure and death from shock.
[0004] Gram-negative bacteria have an outer membrane that Gram-positive bacteria do not have, so drugs are basically difficult to penetrate. In addition, due to the bacterial membrane produced by Gram-negative bacteria through quorum sensing, high concentrations of antibiotics are required, and the effective period of drugs after administration is also short, which may lead to the overuse of antibiotics and drug resistance problems. However, by using quorum sensing inhibitors to inhibit the formation of bacterial membranes of Gram-negative bacteria and control the virulence of bacteria, the progression of related diseases can be fundamentally prevented (see Fig. 9 and 10 ).
[0005] In particular, when quorum sensing inhibitors are administered together with antibiotics, they increase the efficacy of antibiotics by counteracting bacterial membrane effects, thereby reducing effective concentrations and prolonging effective duration, which can increase the effect of antibiotics and minimize the induction of resistance.
[0006] There is a need to develop a novel therapeutic agent that targets Gram-negative bacteria (e.g., Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Porphyromonas gingivalis, etc.) that cause various inflammations, such as sepsis (a systemic inflammatory response syndrome), as well as periodontitis, osteomyelitis, urinary tract infection, cystitis, abdominal infection, or pneumonia.
[0007] At the same time, the inflammasome inflammatory complex may be activated due to Gram-negative bacterial infection and other reasons, thereby inducing immune response, and over-activated NLRP3 inflammasomes cause various inflammasome-mediated diseases, such as neurodegenerative diseases, autoinflammatory diseases and cancer. Therefore, it is necessary to develop a therapeutic agent that can effectively treat diseases by inhibiting NLRP3 inflammasomes. Summary of the invention
[0008] Technical issues
[0009] One embodiment of the present application provides a novel compound of the following Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof:
[0010] [Chemical formula 1]
[0011]
[0012] Another embodiment provides a composition (pharmaceutical composition, food composition, feed composition, etc.) for preventing, alleviating and / or treating inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, for protecting nerve cells and / or regenerating (or generating) nerve cells, comprising one or more selected from the group consisting of the compound of Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof as an active ingredient.
[0013] Another embodiment provides one or more selected from the group consisting of the compound of Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof for preventing, alleviating and / or treating inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, for protecting nerve cells and / or regenerating (or generating) nerve cells.
[0014] Some embodiments provide a use of one or more compounds selected from the group consisting of the compounds of Chemical Formula 1, their isomers, and pharmaceutically acceptable salts thereof in the preparation of a composition (pharmaceutical composition, food composition, feed composition, etc.) for preventing, alleviating, and / or treating inflammasome-mediated diseases; and / or Gram-negative bacterial infections or diseases caused by Gram-negative bacteria, for protecting nerve cells and / or regenerating (or generating) nerve cells.
[0015] Some embodiments provide a method for preventing, alleviating and / or treating inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, a method for protecting nerve cells, and / or regenerating or generating nerve cells, the method comprising administering to a subject (individual) who needs to prevent, improve and / or treat inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, protect nerve cells and / or regenerate or generate nerve cells an effective amount of one or more selected from the group consisting of a compound of Formula 1, its isomers and pharmaceutically acceptable salts thereof.
[0016] Some embodiments provide an antibiotic comprising the compound of Chemical Formula 1. The antibiotic may exhibit antibiotic activity against Gram-negative bacteria.
[0017] The antibiotic (first antibiotic) provided by the present invention is used in combination with another antibiotic (second antibiotic), thereby having the advantages of being able to show the effect of improving the antibiotic sensitivity of bacteria, improving the bactericidal effect of the second antibiotic due to the antibacterial effect of the first antibiotic itself, and being able to exert an excellent antibiotic effect even when a low concentration of the second antibiotic is used. Therefore, side effects such as toxicity (such as nephrotoxicity, hepatotoxicity, etc.) caused by the use of high concentrations of antibiotics can be reduced. In addition, the emergence of antibiotic-resistant bacteria can be suppressed by the combined use of antibiotics with different mechanisms.
[0018] In this regard, one embodiment provides a combination antibiotic comprising:
[0019] Compounds; and
[0020] Second antibiotic.
[0021] Some embodiments provide a feed additive comprising an antibiotic or a combination of antibiotics as an active ingredient.
[0022] Some embodiments provide a disinfectant comprising an antibiotic or a combination of antibiotics as an active ingredient.
[0023] Some embodiments provide a method of disinfection comprising administering an antibiotic or a combination of antibiotics to a subject in need of disinfection.
[0024] Some embodiments provide a cleaning agent comprising an antibiotic or a combination of antibiotics as an active ingredient.
[0025] Some embodiments provide a method of cleaning comprising administering an antibiotic or combination of antibiotics to a subject in need of cleaning.
[0026] Technical Solution
[0027] One embodiment of the present application provides a compound of the following Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof:
[0028] [Chemical formula 1]
[0029]
[0030] Definition of terms
[0031] The following is a brief explanation of the terms used in this article.
[0032] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound that does not cause significant irritation to the organism to which the compound is administered, nor does it eliminate the biological activity and properties of the compound. In the present invention, "pharmaceutically acceptable salts" collectively refer to any salt that also retains the biological effectiveness and properties of the compound of Chemical Formula 1 and is preferred in terms of pharmaceutical, biological or other properties. Pharmaceutically acceptable salts may include acid addition salts formed by acids capable of forming non-toxic acid addition salts containing pharmaceutically acceptable anions, such as inorganic acids, such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc.; organic carbonic acid, such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc.; or sulfonic acid, such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. As a specific example thereof, an acid addition salt of a compound of an embodiment can be prepared by reacting the free base form of these compounds with a stoichiometric amount of an appropriate acid. At this time, the reaction can be carried out in water, an organic solvent or a mixture thereof, specifically, in a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, acetonitrile, etc. In addition, according to the form of a pharmaceutically acceptable salt, each form of salt can be obtained by a typical reaction that is obvious to those skilled in the art. Further, the pharmaceutically acceptable salt can be an alkali metal salt or an alkaline earth metal salt formed by lithium, sodium, potassium, calcium, magnesium, etc., such as lysine, arginine, guanidine, and other amino acid salts, such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline, triethylamine, and other organic salts.
[0033] As used herein, the term "isomer" refers to a compound or salt thereof having the same chemical formula or molecular formula but different optical or geometric structures. Isomers, salts thereof and mixtures thereof (racemic mixtures) are also included within the scope of the present invention.
[0034] As used herein, the term "aryl" refers to a carbocyclic group having a covalent π electron system and having at least one ring (eg, phenyl). The term includes monocyclic or fused polycyclic (ie, rings that share adjacent pairs of carbon atoms) groups.
[0035] As used herein, the term "heteroaryl" refers to a heterocyclic aromatic group having a covalent π electron system and having at least one ring, such as furan, thiophene, pyrrole, imidazole, Azoles, Isopropylamine Azoles, The compounds include, but are not limited to, diazole, tetrazole, thiazole, imidazole, pyrazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
[0036] The aryl and / or heteroaryl group may be substituted or unsubstituted C5-10, which may be an aryl and / or heteroaryl group having: 5 to 10 carbon atoms (C5-C10), 5 to 9 carbon atoms (C5-C9), 5 to 8 carbon atoms (C5-C8), 5 to 7 carbon atoms (C5-C7), 5 to 6 carbon atoms (C5-C6), 6 to 10 carbon atoms (C6-C10), 6 to 9 carbon atoms (C6-C9), 6 to 8 carbon atoms (C6-C8), 6 to 7 carbon atoms (C6-C7), 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms or 10 carbon atoms.
[0037] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon group. The alkyl moiety can be a "saturated alkyl" that does not include an alkenyl or alkynyl moiety, or an "unsaturated alkyl" that includes at least one alkenyl or ethynyl moiety. The "alkene" moiety refers to a group containing at least one carbon-carbon double bond, and the "alkyne" moiety refers to a group containing at least one carbon-carbon triple bond. For example, "alkyl" can be a saturated alkyl, or an unsaturated alkyl with a straight chain, branched chain or cyclic structure. Typical alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, amyl, hexyl, vinyl, propenyl, butenyl, etc. For example, C1-C4-alkyl has 1 to 4 carbon atoms in the alkyl chain, and is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
[0038] The alkyl group used herein can be C 1-10 Straight or branched alkyl, alkoxy can be C 1-10 Straight chain or branched alkoxy. 1-10 Straight or branched chain alkyl, or C 1-10The straight chain or branched alkoxy group may each independently be a group having 1 to 10 carbon atoms (C1-C10), 1 to 9 carbon atoms (C1-C9), 1 to 8 carbon atoms (C1-C8), 1 to 7 carbon atoms (C1-C7), 1 to 6 carbon atoms (C1-C6), 1 to 5 carbon atoms (C1-C5), 1 to 4 carbon atoms (C1-C4), 1 to 3 carbon atoms (C1-C3), 1 to 2 carbon atoms (C1-C2), 1 carbon atom (C1), 2 to 10 carbon atoms (C2-C10), 2 to 9 carbon atoms (C2-C9) , 2 to 8 carbon atoms (C2-C8), 2 to 7 carbon atoms (C2-C7), 2 to 6 carbon atoms (C2-C6), 2 to 5 carbon atoms (C2-C5), 2 to 4 carbon atoms (C2-C4), 2 to 3 carbon atoms (C2-C3), 2 carbon atoms (C2), 3 to 10 carbon atoms (C3-C10), 3 to 9 carbon atoms (C3-C9), 3 to 8 carbon atoms (C3-C8), 3 to 7 carbon atoms (C3-C7), 3 to 6 carbon atoms (C3-C6), 3 to 5 carbon atoms (C3-C5), 3 to 4 carbon atoms (C 3-C4), 3 carbon atoms (C3), 4 to 10 carbon atoms (C4-C10), 4 to 9 carbon atoms (C4-C9), 4 to 8 carbon atoms (C4-C8), 4 to 7 carbon atoms (C4-C7), 4 to 6 carbon atoms (C4-C6), 4 to 5 carbon atoms (C4-C5), 4 carbon atoms (C4), 5 to 10 carbon atoms (C5-C10), 5 to 9 carbon atoms (C5-C9), 5 to 8 carbon atoms (C5-C8), 5 to 7 carbon atoms (C5-C7), 5 to 6 carbon atoms (C5-C6), 5 carbon atoms (C 5), 6 to 10 carbon atoms (C6-C10), 6 to 9 carbon atoms (C6-C9), 6 to 8 carbon atoms (C6-C8), 6 to 7 carbon atoms (C6-C7), 6 carbon atoms (C6), 7 to 10 carbon atoms (C7-C10), 7 to 9 carbon atoms (C7-C9), 7 to 8 carbon atoms (C7-C8), 7 carbon atoms (C7), 8 to 10 carbon atoms (C8-10), 8 to 9 carbon atoms (C8-C9), 9 carbon atoms (C9), 9 to 10 carbon atoms (C9-C10) or 10 carbon atoms (C10).
[0039] As used herein, the term "halo" or "halogen" refers to fluorine (-F), chlorine (-Cl), bromine (-Br), or iodine (-I).
[0040] As used herein, the term "heterocycle" refers to a group in which a cyclic carbon is substituted by oxygen, nitrogen, sulfur, etc., and the group may contain any double bonds. The heterocycle may be, for example, pyrroline, pyrrolidine, tetrahydrofuran, imidazoline, imidazolidinone, pyrazoline, pyrazolidine, pyran, piperidine, piperazine, morpholine, thiomorpholine, etc., but is not limited thereto.
[0041] The term "each independently substituted" means that when the number of substitutable hydrogen atoms is two or more, each hydrogen may be substituted with the same or different substituents.
[0042] As used herein, the term "prevention" refers to any effect of inhibiting or delaying the onset of a disease (disorder) by administering a composition according to one embodiment, the term "treatment" refers to any effect of improving or beneficially changing the symptoms of suspected and morbid individuals by administering a composition according to one embodiment, and the term "improvement" refers to any effect of reducing at least one parameter associated with the disorder to be treated, such as the severity of the symptoms. The disease may be an inflammasome-mediated disease.
[0043] As used herein, the term "pharmaceutically effective amount" refers to the amount of the active ingredient sufficient to obtain the desired pharmaceutical effect, and, as the case may be, refers to the concentration of the active ingredient in the pharmaceutical composition or the dosage administered, which is sufficient to obtain the desired pharmaceutical effect.
[0044] Terms other than the above terms may be construed as meanings generally understood by those skilled in the art to which the present invention belongs.
[0045] Compound of Chemical Formula 1
[0046] One embodiment of the present application provides a compound of the following Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof:
[0047] [Chemical formula 1]
[0048]
[0049] Wherein, in Chemical Formula 1,
[0050] Can be substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C 3-7 Cycloalkenyl, substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 3-7 Heterocycloalkyl, substituted or unsubstituted C containing one or more double bonds and containing one or more heteroatoms selected from the group consisting of N, O and S 3-7 Heterocycloalkenyl, substituted or unsubstituted C 6-10aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 In one embodiment, Can be substituted or unsubstituted C 6-10 Aryl.
[0051] The substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted aryl or substituted heteroaryl may be selected from hydroxy (-OH), halogen (-F, -Br, -Cl or -I), cyano (-CN), nitro (-NO2), amino (-NH), substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 The group consisting of linear or branched alkoxy is substituted by one or more substituents. (As used herein, "substituted by one or more" includes the case of being substituted by two or more identical substituents: for example, the case of being substituted by two OH groups, etc.).
[0052] The substituted alkyl or substituted alkoxy group may be selected from hydroxyl (-OH), halogen, cyano (-CN), nitro (-NO2), amino (-NH), C 1-5 Straight or branched alkyl and C 1-5 The linear or branched alkoxy group may be substituted with one or more substituents selected from the group consisting of linear or branched alkoxy groups.
[0053] R3 can be substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 3-7 Heterocycloalkyl, substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 In one embodiment, R3 can be substituted or unsubstituted C 6-10 Aryl.
[0054] The substituted alkyl group may be selected from hydroxyl (-OH), halogen, cyano (-CN), nitro (-NO2), amino (-NH), C 1-5 Straight or branched alkyl, C 1-5 One or more substituents selected from the group consisting of linear or branched alkoxy groups; or substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 Heteroaryl substitution.
[0055] The substituted alkoxy, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl may be selected from hydroxy (-OH), halogen, cyano (-CN), nitro (-NO2), amino (-NH), C 1-5 Straight or branched alkyl and C 1-5 The linear or branched alkoxy group may be substituted with one or more substituents selected from the group consisting of linear or branched alkoxy groups.
[0056] R1 and R2 may each independently (or both) be hydrogen (H), halogen (-F, -Br, -Cl or -I), substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 In one embodiment, R1 and R2 can each independently be a substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 In one embodiment, the substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted C 5-10 The heteroaryl group may be substituted with one or more substituents selected from the group consisting of a methyl group, an ethyl group, a methoxy group, and an ethoxy group.
[0057] The substituted alkyl group may be selected from hydroxyl (-OH), halogen, cyano (-CN), nitro (-NO2), amino (-NH), C 1-5 Straight or branched alkyl and C 1-5 One or more substituents selected from the group consisting of linear or branched alkoxy groups; or substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 Heteroaryl substitution.
[0058] The substituted alkoxy, substituted aryl, and substituted heteroaryl may be selected from hydroxyl (-OH), halogen, cyano (-CN), nitro (-NO2), amino (-NH), C 1-5 Straight or branched alkyl and C 1-5 The linear or branched alkoxy group may be substituted with one or more substituents selected from the group consisting of linear or branched alkoxy groups.
[0059] In one embodiment, the compound of Chemical Formula 1 may be one or more selected from the group consisting of the following compounds:
[0060] 1) 3-(diphenylmethylene)-2-methylisoindolin-1-one,
[0061] 2) 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and
[0062] 3) 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
[0063] Some embodiments of the present application provide a compound of the following Chemical Formula 1A, an isomer thereof, or a pharmaceutically acceptable salt thereof:
[0064] [Chemical Formula 1A]
[0065]
[0066] Wherein, in Chemical Formula 1A,
[0067] R1, R2 and R3 are as defined above. However, the compound of Formula 1A may not include the following compounds:
[0068] 3-(Diphenylmethylene)-2-methylisoindolin-1-one (CAS No. 92172-54-8).
[0069] In one embodiment, the compound of Chemical Formula 1A may be one or more selected from the group consisting of the following compounds:
[0070] 1) 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and
[0071] 2) 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
[0072] The isomer of the compound of chemical formula 1 or chemical formula 1A (hereinafter, unless otherwise specified, the compound of chemical formula 1 or chemical formula 1A is uniformly described as the compound of chemical formula 1) can be an optical isomer, a stereoisomer or a mixture of isomers (racemic mixture) of the compound of formula 1. In the compound of chemical formula 1 according to one embodiment, it should be understood that each substituent can be connected to the chiral center of the carbon atom. In addition, any asymmetric carbon atom on the compound of one embodiment can exist in any form of (R)-, (S)- or (R, S)-configuration, and is suitably present in (R)- or (S)-configuration, wherein each configuration is an independent form. In addition, the compound of one embodiment can exist in any possible isomeric form or a mixture thereof, for example, can exist in any form of pure geometric isomers, diastereomers, optical isomers, racemates or mixtures thereof. In addition, when the compound of one embodiment has a double bond, each substituent connected to the double bond can be an E or Z configuration.
[0073] Inflammasome-mediated diseases
[0074] The term "inflammasome" as used herein refers to a multiprotein complex of semi-activated caspase-1, and may include 1) NLR (nucleotide binding oligomerization domain and leucine-rich repeat receptor) protein, which is a sensor protein, 2) ASC (adaptor protein apoptosis-associated spec-like protein containing a caspase-recruitment domain), which is an adaptor protein, and 3) pro-caspase-1, which is an effector protein. IL-1β is one of the inflammatory cytokines, formed by a multiprotein polymer called an inflammasome, and can mediate cell pyroptosis, which is a type of inflammatory cell apoptosis. In the case of inflammasomes, when pathogen-associated molecular pattern molecules (PAMPs) or damage-associated molecular pattern molecules (DAMPs) produced by dead cells activate Toll-like receptors (TLRs), the expression of IL-1β precursor (pro-IL-1β) increases, and then caspase-1 is activated by a protein complex called inflammasome to degrade IL-1β precursor, thereby enabling the production of activated IL-1β.
[0075] Inflammasomes may be selected from the group consisting of NLRP3 (NOD-like receptor family, containing pyrin domain 3) inflammasomes, AIM2 (absent in melanoma 2) inflammasomes and NLRC4 (protein 4 containing NLR family CARD domain) inflammasomes, but are not limited thereto. NLRP3, AIM2 or NLRC4 inflammasomes are meant to include nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide chains, complementary sequences, peptides, polypeptides, proteins, homologous and / or orthologous molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species and active fragments thereof, but are not limited thereto.
[0076] If the inflammasome is overactivated, an inflammasome-mediated disease may occur. The activation of the inflammasome may be caused by Gram-negative bacterial infection or Gram-negative bacteria, but is not limited thereto. In one embodiment, the compound of the present application can inhibit the activation of the inflammasome (e.g., inhibiting the production of inflammatory cytokines IL-1β, etc.), thereby effectively regulating the secretion of the inflammatory cytokine IL-1β, thereby showing excellent effects in preventing, alleviating or treating inflammasome-mediated diseases.
[0077] Inflammasome-mediated diseases can refer to any type of disease that occurs when the inflammasome is abnormally and overactivated.
[0078] In one embodiment, the inflammasome-mediated disease may be periodontal disease.
[0079] In one embodiment, the inflammasome-mediated disease may be a neurodegenerative disease.
[0080] In one embodiment, the inflammasome-mediated disease may be an inflammatory disease. The inflammatory disease may be an inflammasome-mediated inflammatory disease.
[0081] In one embodiment, the inflammasome-mediated disease may be cancer.
[0082] In one embodiment, the inflammasome-mediated disease may be a Gram-negative bacterial infection or a disease caused by Gram-negative bacteria.
[0083] In one embodiment, the inflammasome-mediated disease can be one or more selected from the group consisting of periodontal disease, neurodegenerative diseases, inflammatory diseases (e.g., inflammasome-mediated inflammatory diseases), cancer, Gram-negative bacterial infection or diseases caused by Gram-negative bacteria, metabolic diseases, sepsis, septic shock, inflammatory bowel disease, osteoarthritis, hyperimmunoglobulin D syndrome, and cold and heat protein-associated periodic syndrome, but is not limited thereto.
[0084] The compounds of the present application exhibit antibiotic effects against Gram-negative bacteria, specifically, have inhibitory activity against the virulence of Porphyromonas sp. bacteria, as described below, and may have preventive, ameliorative and / or therapeutic activity against periodontal disease.
[0085] The inhibitory activity against the toxicity of Gram-negative bacteria can be achieved by inhibiting the quorum sensing of Gram-negative bacteria and / or inhibiting the expression of virulence factors of Gram-negative bacteria (e.g., biofilm of Gram-negative bacteria, or gingipain in the case of Porphyromonas bacteria, etc.) (e.g., inhibiting the mRNA transcription process, or inhibiting the protein translation process, etc.), but is not limited thereto. Gingipain can be one or more selected from the group consisting of lysine-gingipain (Kgp), arginine-gingipain A (RgpA), arginine-gingipain B (RgpB), etc., but is not limited thereto.
[0086] By inhibiting the virulence of Gram-negative bacteria, the prevention, improvement and / or treatment of periodontal disease can be achieved. That is, the prevention, improvement and / or treatment of periodontal disease includes inhibiting the virulence of Gram-negative bacteria, for example, inhibiting the quorum sensing of Porphyromonas bacteria, and / or inhibiting virulence factors (e.g., gingipains, biofilms, etc.) in Porphyromonas bacteria (e.g., inhibiting the transcription process of mRNA or inhibiting the translation process of protein, etc.), but is not limited thereto.
[0087] The periodontal disease may be one or more diseases selected from periodontitis, gingivitis, and the like.
[0088] The compounds of the present application may be characterized by having the activity of inhibiting the expression of inflammatory proteins (such as inflammatory cytokines, etc.) in patients with neurodegenerative diseases, and inhibiting inflammation and death of nerve cells (neuroinflammation, etc.) and / or death and / or inflammation of neuronal cells caused by Porphyromonas gingivalis.
[0089] Neurodegenerative diseases as used herein can be selected from all diseases that cause motor control ability, cognitive function, perceptual function, sensory function and autonomic nerve function abnormalities due to nerve cell death, reduction, functional decline or loss of function. For example, the neurodegenerative disease can be selected from one or more of the group consisting of dementia (e.g., Alzheimer's disease (AD), vascular dementia, mixed dementia, Lewy body dementia, frontotemporal dementia, etc.), Parkinson's disease (PD), Huntington's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), hand tremor, chorea, multiple sclerosis, motor neuron disease, spinal muscular atrophy, Creutzfeldt-Jakob disease, Pick's disease, prion disease, spinocerebellar ataxia, etc., but is not limited thereto.
[0090] Neurodegenerative diseases may be caused by Gram-negative bacterial infection, such as Porphyromonas bacteria, or may be induced by Porphyromonas bacteria, but are not limited thereto. Porphyromonas bacteria may be one or more selected from the group consisting of Porphyromonas gingivalis, Porphyromonas endodontalis, and the like.
[0091] The neural cell may be a central nervous cell, such as a brain (neural) cell.
[0092] Inflammatory proteins (such as inflammatory cytokines) may be IL-6, IL-8, IL-18, TNF-α, IL-1, etc., but are not limited thereto.
[0093] Inflammatory diseases may be abnormal inflammatory diseases that occur when inflammasomes are abnormal and overactivated, and may include neuroinflammatory diseases, autoinflammatory diseases, autoimmune diseases, etc.
[0094] Neuroinflammatory diseases may refer to diseases caused by damage to neural tissue due to inflammatory response, and may be one or more selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Lou Gehrig's disease, Creutzfeldt-Jakob disease, multiple sclerosis, amyotrophic lateral sclerosis, inflammatory spinal cord injury, diffuse Lewy body disease, leukoencephalitis, temporal lobe epilepsy and inflammatory spinal cord injury, but are not limited thereto.
[0095] The autoinflammatory disease can be one or more selected from the group consisting of Muckle-Wells syndrome (MWS), latent autoimmune diabetes in adults (LADA), familial cold autoinflammatory syndrome (FCAS), cryopyrin-associated periodic syndrome (CAPS), neonatal-onset multisystem inflammatory syndrome (NOMID), chronic infantile neurocutaneous and articular syndrome (CINCA), familial Mediterranean fever (FMF), juvenile arthritis (e.g., systemic juvenile idiopathic arthritis (SJIA)), juvenile rheumatoid arthritis (e.g., systemic juvenile idiopathic rheumatoid arthritis) and gout, but is not limited thereto.
[0096] The autoimmune disease may be one or more selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), atopic dermatitis (AD) and psoriasis, but is not limited thereto.
[0097] In addition, it is known that the activation of inflammasomes is involved in the pathogenesis of various cancers, wherein the cancer can be selected from colorectal cancer, acute myeloid leukemia, adrenocortical carcinoma, Kaposi's sarcoma, lymphoma, anal cancer, appendix cancer, teratoid / rhabdomyosarcoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumors, carcinoid tumors, heart tumors, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative tumors, colon cancer, colorectal cancer, craniopharyngioma, endometrial cancer, ependymoma, esophageal cancer, sensorineuroblastoma, Ewing's sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, One or more of the group consisting of, but not limited to, germ cell tumors, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopharyngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myeloid leukemia, lip cancer, oral cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, intraoral cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, laryngeal cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer and vulvar cancer.
[0098] The compounds of the present application can inhibit inflammasomes, thereby effectively preventing, improving or treating cancer.
[0099] Metabolic diseases are a general term for diseases caused by metabolic disorders of an organism, and may be one or more selected from obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), but are not limited thereto.
[0100] Antibiotics that are effective against Gram-negative bacteria and Gram-negative infections or diseases caused by Gram-negative bacteria
[0101] Another embodiment provides an antibiotic comprising the above compound.
[0102] Some embodiments provide the use of the compound as an antibiotic against Gram-negative bacteria (eg, inhibiting (or suppressing) the growth of Gram-negative bacteria, inhibiting Gram-negative bacteria, sterilizing and preventing harm caused by Gram-negative bacteria, etc.).
[0103] Some embodiments provide a method for sterilizing Gram-negative bacteria (or a bacteriostatic method, a hazard control method, or a growth inhibition method), comprising the step of administering (or administering) an effective amount of a compound to a subject in need of resistance to Gram-negative bacteria (or bacteriostasis, sterilization, hazard control, etc. of Gram-negative bacteria).
[0104] Some embodiments provide use of the compound for preparing antibiotics.
[0105] Bacteriostatic action may refer to an antibiotic that binds irreversibly to bacteria and does not kill them, but inhibits their growth. Bactericidal action may refer to an antibiotic that binds irreversibly to bacteria and kills them, rather than inhibiting their growth. The distinction between bacteriostatic and bactericidal action is not absolute, and they can be used together and act as either bacteriostatics or bactericides, depending on the concentration of antibiotic administered.
[0106] The compound of Chemical Formula 1 may have (i) inhibitory activity against the virulence of Gram-negative bacteria, (ii) antibiotic effect (e.g., bacteriostatic effect and / or bactericidal effect) against Gram-negative bacteria, and / or (iii) preventive, ameliorative and / or therapeutic activity against Gram-negative bacteria infection or diseases caused by Gram-negative bacteria.
[0107] The inhibitory activity against the virulence of Gram-negative bacteria, or the antibiotic effect against Gram-negative bacteria, can be achieved by inhibiting the quorum sensing of Gram-negative bacteria, and / or inhibiting the expression of virulence factors (such as biofilms, extracellular polysaccharides (EPS), toxins, etc.) of Gram-negative bacteria (such as inhibiting the transcription process of mRNA, or inhibiting the translation process of protein, etc.), but is not limited to this.
[0108] The prevention, improvement and / or treatment of Gram-negative bacteria infection or diseases caused by Gram-negative bacteria can be achieved by inhibiting the virulence of Gram-negative bacteria or the antibiotic effect against Gram-negative bacteria. That is, Gram-negative bacteria infection or diseases caused by Gram-negative bacteria (e.g., inhibiting the transcription process of mRNA or inhibiting the translation process of protein, etc.) can be prevented, improved and / or treated by inhibiting the quorum sensing of Gram-negative bacteria, or the antibiotic effect against Gram-negative bacteria, for example, by inhibiting the virulence factors (e.g., biofilm, exopolysaccharide (EPS), toxin, etc.) in Gram-negative bacteria, but not limited thereto.
[0109] Antibiotics can have antibiotic effects on gram-negative bacteria. Gram-negative bacteria can be selected from one or more (e.g., one, two, three, four or five) of the group consisting of Escherichia sp.bacterium, Pseudomonas sp.bacterium, Acinetobacter sp.bacterium, Enterobacter sp.bacterium, Klebsiella sp.bacterium, Porphyromonas sp.bacterium, Fusobacteria sp.bacterium, Tannerella sp.bacterium, etc. For example, the Escherichia bacterium may be Escherichia coli, the Pseudomonas bacterium may be Pseudomonas aeruginosa, the Acinetobacter bacterium may be Acinetobacter baumannii, the Enterobacter bacterium may be Enterobacter aerogenes (also known as Klebsiella aerogenes or Enterobacter cloacae), the Klebsiella bacterium may be Klebsiella pneumoniae, the Porphyromonas bacterium may be Porphyromonas gingivalis or Porphyromonas endodontalis, the Fusobacterium bacterium may be Fusobacterium nucleatum, the Tannerella bacterium may be Tannerella forsythiae. forsythia), but is not limited thereto.
[0110] Gram-negative bacteria infection or the disease caused by Gram-negative bacteria can be selected from all diseases caused by Gram-negative bacteria infection, for example, it can be one or more selected from the group consisting of enteritis, Crohn's disease, ulcerative colitis, bacillary dysentery, urinary tract infection, skin infection, bacteremia, sepsis, skin infection, bedsore, pneumonia, endocarditis, meningitis, otitis externa, otitis media, keratitis, osteomyelitis, peritonitis, periodontitis, cystic fibrosis and periodontal disease (such as gingivitis, peritonitis, etc.), but is not limited thereto.
[0111] Gram-negative bacterial infections or diseases caused by Gram-negative bacteria can be selected from diseases caused by, for example, Escherichia bacteria, such as enteritis, Crohn's disease, ulcerative colitis, bacillary dysentery, urinary tract infection, skin infection, bacteremia, sepsis; diseases caused by Pseudomonas bacteria, such as skin infection, bedsores, pneumonia, bacteremia, sepsis, endocarditis, meningitis, otitis externa, otitis media, keratitis, osteomyelitis, enteritis, periodontitis and cystic fibrosis; diseases caused by Acinetobacter bacteria, such as skin infection, pneumonia, bacteremia and sepsis; diseases caused by Porphyromonas bacteria, Fusobacterium bacteria or Tannerella bacteria, such as gingivitis, periodontitis, etc., but are not limited thereto.
[0112] The antibiotic provided by the present invention can be used in combination with other antibiotics (second antibiotics) in addition to the above compounds.
[0113] Therefore, in another aspect, there is provided a combination antibiotic comprising the antibiotic and a second antibiotic.
[0114] The combined antibiotic may have an antibiotic effect against Gram-negative bacteria. The Gram-negative bacteria are the same as those described above.
[0115] The second antibiotic can be one or more selected from commonly used antibiotics, for example, antibiotics with anti-Gram-negative antibiotic activity. The second antibiotic can be one or more selected from the group consisting of β-lactam antibiotics, bacterial cell membrane permeability inhibitors, bacterial ribosome inhibitors, bacterial nucleic acid synthesis inhibitors and bacterial folate synthesis inhibitors.
[0116] In a specific embodiment, the second antibiotic may be one or more selected from the group consisting of:
[0117] β-lactam antibiotics;
[0118] One or more bacterial cell membrane permeability inhibitors selected from the group consisting of polymicin, amphotericin B, ketoconazole, fluconazole, itraconazole, etc.;
[0119] One or more bacterial ribosomal inhibitors selected from the group consisting of aminoglycosides, tetracyclines, macrolides, lincosamides, chloramphenicol, etc.;
[0120] One or more bacterial nucleic acid synthesis inhibitors selected from the group consisting of quinolones, fluoroquinolones, rifampicin, etc.; and
[0121] One or more bacterial folate synthesis inhibitors selected from the group consisting of sulfonamides, trimethoprim, and the like.
[0122] Beta-lactam antibiotics can include:
[0123] One or more penicillin antibiotics selected from the group consisting of penicillin G, methicillin, oxacillin, flucloxacillin, amoxicillin, ampicillin, ampicillin / sulbactam, piperacillin, piperacillin / tazobactam, ticarcillin, azlocillin, carbenicillin, and amoxicillin / clavulanic acid;
[0124] one or more cephalosporin antibiotics selected from the group consisting of cefazolin, cephalexin, cephalothin, norcephalosporin, cefazolin, cefaclor, cefmandole, cefmetazole, cefotiam, cefuroxime, ceftriaxone, ceftazidime and cefepime;
[0125] Monobactam antibiotics, such as aztreonam; and
[0126] One or more carbapenem antibiotics selected from the group consisting of imipenem, imipenem / cilastatin, faropenem, meropenem, doripenem and atapenem, but not limited thereto.
[0127] A second antibiotic may have improved antibiotic activity when used in combination with a β-lactamase inhibitor such as clavulanic acid, sulbactam or tazobactam, or cilastatin.
[0128] In one embodiment, the second antibiotic can be used in combination with substances such as clavulanic acid, sulbactam, tazobactam, cilastatin, etc., for example, it can be used in combination with amoxicillin / clavulanic acid, ampicillin / sulbactam, piperacillin / tazobactam, imipenem / cilastatin, etc. At this time, the second antibiotic and clavulanic acid, sulbactam, tazobactam, cilastatin, etc. can be used in combination in various ratios, for example, by weight, 1:10-0.1, 1:9-0.1, 1:8-0.1, 1:7-0.1, 1:6-0.1, 1:5-0.1, 1:4-0.1, 1:3-0.1, 1:2-0.1, 1:10-0.2, 1:9-0.2, 1:8-0.2, 1:7-0.2, 1:6-0.2, 1:5-0.2, 1:4-0.2, 1: 3~0.2, 1:2~0.2, 1:10~0.5, 1:9~0.5, 1:8~0.5, 1:7~0.5, 1:6~0.5, 1:5~0.5, 1:4~0.5, 1:3~0.5, 1:2~0.5, 1:10~0.75, 1:9~0.75, 1:8~0.75, 1:7~0.75, 1:6~0.75, 1:5~0.75, 1:4~0.75, 1:3~0.75, 1:2~0.75, 1:2, 1:0.5.
[0129] In addition, the second antibiotic can be used in combination with two or more second antibiotics. When used in combination with two or more second antibiotics, each second antibiotic can be used in combination in various ratios, for example, by weight, 1:10-0.1, 1:9-0.1, 1:8-0.1, 1:7-0.1, 1:6-0.1, 1:5-0.1, 1:4-0.1, 1:3-0.1, 1:2-0.1, 1:10-0.2, 1:9-0.2, 1:8-0.2, 1:7-0.2, 1:6-0.2, 1:5-0. 2. 1:4~0.2, 1:3~0.2, 1:2~0.2, 1:10~0.5, 1:9~0.5, 1:8~0.5, 1:7~0.5, 1:6~0.5, 1:5~0.5, 1:4~0.5, 1:3~0.5, 1:2~0.5, 1:10~0.75, 1:9~0.75, 1:8~0.75, 1:7~0.75, 1:6~0.75, 1:5~0.75, 1:4~0.75, 1:3~0.75, 1:2~0.75, 1:2, 1:0.5.
[0130] The combined use of an antibiotic (first antibiotic) and another antibiotic (second antibiotic) in this manner has the advantages of being able to improve the antibiotic sensitivity of bacteria, improving the bactericidal effect of the second antibiotic due to the antibacterial effect of the first antibiotic itself, and being able to exert an excellent antibiotic effect even when a low concentration of the second antibiotic is used. Alternatively, because the first antibiotic has a quorum sensing inhibition and / or biofilm formation inhibition effect and / or a gram-negative bacteria virulence weakening effect, when the first antibiotic is used in combination with the second antibiotic, the second antibiotic that has an antibiotic effect on gram-negative bacteria can also exert an excellent antibiotic effect even at a low concentration. Therefore, side effects such as toxicity (e.g., nephrotoxicity, hepatotoxicity, etc.) caused by the use of high concentrations of antibiotics can be reduced. In addition, by using antibiotics with different mechanisms in combination, the emergence of antibiotic-resistant bacteria can be suppressed.
[0131] The term "antibiotic" as used herein encompasses all types of agents that have growth inhibition (e.g., quorum sensing inhibition, biofilm formation inhibition, and / or virulence reduction) and / or killing capabilities against Gram-negative bacteria, and unless otherwise indicated, it can be used interchangeably with antimicrobial agents, preservatives, disinfectants, and the like.
[0132] Pharmaceutical composition
[0133] On the other hand, provided is a pharmaceutical composition for preventing or treating inflammasome-mediated diseases and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, which comprises the compound, its isomers and pharmaceutically acceptable salts thereof as active ingredients.
[0134] Some aspects provide a use of one or more selected from the group consisting of the compound of Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof in preventing, alleviating and / or treating inflammasome-mediated diseases; and / or Gram-negative bacterial infection or diseases caused by Gram-negative bacteria.
[0135] Some aspects provide a pharmaceutical composition for preventing, alleviating and / or treating inflammasome-mediated diseases; and / or Gram-negative bacterial infection or diseases caused by Gram-negative bacteria, comprising one or more selected from the group consisting of a compound of Chemical Formula 1, an isomer thereof, and a pharmaceutically acceptable salt thereof.
[0136] Some aspects provide a method for preventing, alleviating and / or treating an inflammasome-mediated disease; and / or a Gram-negative bacterial infection or a disease caused by Gram-negative bacteria, the method comprising administering an effective amount of one or more selected from the group consisting of a compound of Formula 1, its isomers, and a pharmaceutically acceptable salt thereof to a subject who needs to prevent, alleviate and / or treat an inflammasome-mediated disease; and / or a Gram-negative bacterial infection or a disease caused by Gram-negative bacteria. The method may also include a step of identifying a subject who needs to prevent, alleviate and / or treat an inflammasome-mediated disease; and / or a Gram-negative bacterial infection or a disease caused by Gram-negative bacteria before the administration step.
[0137] Some aspects provide a use of one or more selected from the group consisting of the compound of Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof in the preparation of a composition for preventing, alleviating and / or treating an inflammasome-mediated disease; and / or a Gram-negative bacterial infection or a disease caused by Gram-negative bacteria.
[0138] Some embodiments provide a pharmaceutical composition for protecting nerve cells and / or a pharmaceutical composition for regenerating or generating nerve cells, which comprises the above-mentioned compound.
[0139] Some embodiments provide a method for protecting nerve cells and / or a method for regenerating or generating nerve cells, comprising the step of administering the above compound to a subject in need of protecting nerve cells and / or regenerating or generating nerve cells.
[0140] Some aspects provide a use of the above-mentioned compound in preparing a pharmaceutical composition for protecting nerve cells and / or a pharmaceutical composition for regenerating (or generating) nerve cells.
[0141] Hereinafter, unless otherwise specified, the compound of Formula 1 as the active ingredient of the pharmaceutical composition includes all isomers of the compound, and pharmaceutically acceptable salts of the compound or isomers, and all of these compounds, isomers and salts should be deemed to be included within the scope of the present application. However, for ease of description, unless otherwise specified herein, one or more selected from the group consisting of the compound of Formula 1, its isomers and pharmaceutically acceptable salts thereof as the active ingredient of the pharmaceutical composition will be referred to as "the compound of Formula 1".
[0142] Inflammasome-mediated diseases are the same as described above.
[0143] The subject to which the pharmaceutical composition is administered may be selected from mammals, including primates, such as humans and monkeys, rodents, such as mice and rats, livestock, such as dogs, cats, pigs, cattle, horses, sheep and goats; poultry, such as chickens, ducks, geese, pheasants, quails and turkeys, etc., or one or more of the cells, tissues or cultures derived therefrom. For example, the subject to be administered may be a subject who needs to prevent, improve and / or treat an inflammasome-mediated disease; and / or a subject infected with Gram-negative bacteria or a disease caused by Gram-negative bacteria.
[0144] In one embodiment, the subject (patient) to be administered can be selected from mammals suffering from neurodegenerative diseases, including primates, such as humans, apes, etc., and rodents, such as rats, mice, etc., cells (brain cells) or tissues (brain tissues) isolated from mammals, or cultures thereof. For example, the subject can be selected from humans suffering from neurodegenerative diseases, brain cells or tissues isolated therefrom, or cultures of cells or tissues.
[0145] A pharmaceutical composition comprising one or more of the group consisting of a compound of formula 1, its isomers and pharmaceutically acceptable salts thereof as an active ingredient can be prepared and used in the form of a typical pharmaceutical preparation. For example, the pharmaceutical preparation can be made into a variety of preparations for oral or parenteral administration, and the type of preparation can be different according to the use, method of administration, purpose of administration, etc. When a variety of preparations for oral or parenteral administration are made, one or more of the group consisting of diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants and surfactants that are commonly used can be used for preparation. When preparing various preparations for oral or parenteral administration, one or more of the group consisting of diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. can be mixed and prepared.
[0146] When the pharmaceutical composition is administered orally, the active drug of the composition should be coated or formulated to prevent the active drug from being degraded in the stomach due to digestion of proteins or peptides. Orally administered solid preparations can include tablets, pills, powders, granules, capsules, etc. Such solid preparations can be prepared by mixing the active ingredient with one or more excipients, for example, one or more excipients selected from the group consisting of starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talcum powder can also be used. In addition, liquid preparations for oral administration can include suspensions, oral liquids, emulsions, syrups, etc. When formulated into liquid preparations, commonly used simple diluents can be used, such as water and / or liquid paraffin, and optionally, one or more selected from the group consisting of various excipients can also be included, for example, wetting agents, sweeteners, spices, preservatives, etc. In addition, the composition can be administered by any device capable of transporting the active agent to the target cell.
[0147] When the pharmaceutical composition is administered parenterally, parenteral administration can be carried out by any convenient route, such as vascular administration (e.g., arterial administration, intravenous administration, etc.), injection or insertion of the patient's lesion site (e.g., gums, etc.), intramuscular administration, subcutaneous administration, peritoneal administration, nasal administration, transdermal administration, intradermal administration, topical administration, intrapulmonary administration, rectal administration, intravenous injection, subcutaneous injection, intramuscular injection, peritoneal injection, but not limited to this. The dosage form of parenteral administration includes sterile aqueous solution, non-aqueous solution, suspension, emulsion, lyophilized agent, suppository, etc. As a non-aqueous solvent for preparing a non-aqueous solution or a suspension solvent for preparing a suspension, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. can be used. As the matrix of the suppository, witepsol, polyethylene glycol, Tween 61, cocoa butter, lauric acid ester, glycerin gelatin, etc. can be used. When administered nasally, the pharmaceutical composition can be diluted and administered by nasal spray, which is absorbed into the nasal cavity by an atomizer or a spray system. For nasal sprays, aerosols or the like can be used as nasal sprays or respiratory preparations.
[0148] Based on the total weight of the pharmaceutical composition, the content of the active ingredient contained in the pharmaceutical composition can be 0.01% to 99.9% by weight, 0.01% to 90% by weight, 0.01% to 80% by weight, 0.01% to 70% by weight, 0.01% to 60% by weight, 0.01% to 50% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 1% to 99.9% by weight, 1% to 90% by weight, 1% to 80% by weight, 1% to 70% by weight, 1% to 60% by weight, 1% to 50% by weight, %, 1 wt % to 40 wt %, 1 wt % to 30 wt %, 5 wt % to 99.9 wt %, 5 wt % to 90 wt %, 5 wt % to 80 wt %, 5 wt % to 70 wt %, 5 wt % to 60 wt %, 5 wt % to 50 wt %, 5 wt % to 40 wt %, 5 wt % to 30 wt %, 10 wt % to 99.9 wt %, 10 wt % to 90 wt %, 10 wt % to 80 wt %, 10 wt % to 70 wt %, 10 wt % to 60 wt %, 10 wt % to 50 wt %, 10 wt % to 40 wt % or 10 wt % to 30 wt %. However, the content is not limited thereto and can be appropriately adjusted according to the formulation form, mode of administration, purpose of administration, etc. In addition, in addition to the active ingredient, the pharmaceutical composition may also include a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is a carrier commonly used to prepare drugs containing proteins, nucleic acids or cells, and may refer to a carrier that does not stimulate an organism and does not inhibit the biological activity and / or properties of an active ingredient. In one embodiment, the carrier may be selected from the group consisting of lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but is not limited thereto. The pharmaceutical composition may also include one or more selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. commonly used when preparing the pharmaceutical composition.
[0149] The pharmaceutically effective amount of the pharmaceutical composition can be differently specified according to various factors such as the preparation method, administration route, excretion rate, patient's reaction sensitivity, etc. The composition can be administered once or multiple times a day, but is not limited thereto, and can be administered in a variety of dosages and methods. In one embodiment, a single dose of the pharmaceutical composition may be in the following ranges: 0.0001-5000 mg / kg, 0.0001-4000 mg / kg, 0.0001-3000 mg / kg, 0.0001-2500 mg / kg, 0.0001-2000 mg / kg, 0.0001-1500 mg / kg, 0.0001-1000 mg / kg, 0.0001-500 mg / kg, 0.0001-100 mg / kg, 0.0001-50 mg / kg, 0.0001-10 mg / kg, 0.0001-5 mg / kg, 0.0001-1 mg / kg, 0.001~5000mg / kg, 0.001~4000mg / kg, 0.001~3000mg / kg, 0.001~2500mg / kg, 0.001~2000mg / kg, 0.001~1500mg / kg, 0.001~1000mg / kg, 0.001~500mg / kg, 0.001~100mg / kg, 0.001~50mg / kg, 0.001 ~10mg / kg, 0.001~5mg / kg, 0.001~1mg / kg, 0.01~5000mg / kg, 0.01~4000mg / kg, 0.01~3000mg / kg, 0.01 ~2500mg / kg, 0.01~2000mg / kg, 0.01~1500mg / kg, 0.01~1000mg / kg, 0.01~500mg / kg, 0.01~100mg / kg, 0.01~50mg / kg, 0.01~10mg / kg, 0.01~5mg / kg, 0.01~1mg / kg, 0.1~5000mg / kg, 0.1~4000mg / kg, 0.1~30 00mg / kg, 0.1~2500mg / kg, 0.1~2000mg / kg, 0.1~1500mg / kg, 0.1~1000mg / kg, 0.1~500mg / kg, 0.1~100 mg / kg, 0.1~50mg / kg, 0.1~10mg / kg, 0.1~5mg / kg, 0.1~1mg / kg, 1~5000mg / kg, 1~4000mg / kg, 1~3000mg / kg, 1~2500mg / kg, 1~2000mg / kg, 1~1500mg / kg, 1~1000mg / kg, 1~500mg / kg, 1~100mg / kg, 1~50mg / kg,1 - 10 mg / kg, 1 - 5 mg / kg, 5 - 5000 mg / kg, 5 - 4000 mg / kg, 5 - 3000 mg / kg, 5 - 2500 mg / kg, 5 - 2000 mg / kg, 5 - 1500 mg / kg, 5 - 1000 mg / kg, 5 - 500 mg / kg, 5 - 100 mg / kg, 5 - 50 mg / kg, 5 - 10 mg / kg, 10 - 5000 mg / kg, 10 - 4000 mg / kg, 10 - 3000 mg / kg, 10 - 2500 mg / kg, 10 - 2000 mg / kg, 10 - 1500 mg / kg, 10 - 1000 mg / kg, 10 - 500 mg / kg, 10 - 100 mg / kg, 10 - 50 mg / kg, 20 - 5000 mg / kg, 20 - 4000 mg / kg, 20 - 3000 mg / kg, 20 - 2500 mg / kg, 20 - 2000 mg / kg, 20 - 1500 mg / kg, 20 - 1000 mg / kg, 20 - 500 mg / kg, 20 - 100 mg / kg, 20 - 50 mg / kg, 50 - 5000 mg / kg, 50 - 4000 mg / kg, 50 - 3000 mg / kg, 50 - 2500 mg / kg, 50 - 2000 mg / kg, 50 - 1500 mg / kg, 50 - 1000 mg / kg, 50 - 500 mg / kg, 50 - 100 mg / kg, 100 - 5000 mg / kg, 100 - 4000 mg / kg, 100 - 3000 mg / kg, 100 - 2500 mg / kg, 100 - 2000 mg / kg, 100 - 1500 mg / kg, 100 - 1000 mg / kg, 100 - 500 mg / kg, 200 - 5000 mg / kg, 200 - 4000 mg / kg, 200 - 3000 mg / kg, 200 - 2500 mg / kg, 200 - 2000 mg / kg, 200 - 1500 mg / kg, 200 - 1000 mg / kg, 200 - 500 mg / kg, 500 - 5000 mg / kg, 500 - 4000 mg / kg, 500 - 3000 mg / kg, 500 - 2500 mg / kg, 500 - 2000 mg / kg, 500 - 1500 mg / kg, 500 - 1000 mg / kg, 1500 - 5000 mg / kg, 1500 - 4000 mg / kg, 1500 - 3000 mg / kg, 1500 - 2500 mg / kg, 1500 - 2000 mg / kg, 2000 - 5000 mg / kg, 2000 - 4000 mg / kg, 2000 - 3000 mg / kg or 2000 - 2500 mg / kg, but not limited thereto.
[0150] Food composition
[0151] Another embodiment provides a food composition for preventing and / or treating inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, for protecting nerve cells and / or regenerating (or generating) nerve cells, which comprises the above-mentioned compound.
[0152] The food composition can be a health functional food.
[0153] Inflammasome-mediated diseases; and / or Gram-negative bacterial infections or diseases caused by Gram-negative bacteria are the same as above.
[0154] The food composition according to one embodiment may refer to meat, sausage, bread, chocolate, candy, snacks, preserves, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, health drinks, alcoholic beverages, vitamin complexes, health functional foods and health foods, etc., and includes all foods considered within the conventional meaning.
[0155] The term "health functional food" is the same as the term "food for specific health use" (FoSHU), which refers to a food that has high medical and medicinal effects and is processed to effectively exhibit biological regulatory functions in addition to nutritional supply. As used herein, the term "functional" refers to nutrients that control the structure or function of the human body or provide effects that are beneficial to health purposes, such as physiological effects. The food of the present application can be produced by methods commonly used in the art, and can be prepared by adding raw materials and ingredients commonly used in the art. In addition, the dosage form of the food can be produced in various dosage forms without restriction, as long as it is a dosage form recognized as food. The food composition of the present application can be made into various dosage forms, and unlike general medicines, it has the advantages that side effects that may occur when taking drugs for a long time will not be caused by using food as a raw material, and has the advantage of excellent portability. Therefore, the food of the present application can be taken as a supplement to promote the effect of preventing or alleviating inflammatory diseases mediated by inflammasomes.
[0156] Health food refers to food that has the function of maintaining or promoting health compared with general food, and health supplement food refers to food used for health purposes. The terms health functional food, health food and health supplement food can be used interchangeably in some cases.
[0157] Specifically, health functional food is a food made by adding the composition according to one embodiment to food materials (such as beverages, teas, spices, chewing gum and candies), or by encapsulating, powdering or suspending it, and means that they provide special health effects during intake. The advantage of the health functional food is that, unlike general drugs, the side effects that may occur when taking drugs for a long time will not occur due to the use of food as a raw material.
[0158] Since the food composition according to one embodiment can be taken daily, it can be expected to have an excellent effect in preventing or alleviating inflammasome-mediated inflammatory diseases and can therefore be very usefully used.
[0159] Food composition can also include physiologically acceptable carrier, but the type of carrier is not particularly limited, and any carrier commonly used in the art can be used. In addition, food composition can contain additional ingredients that are commonly used in food composition to enhance smell, taste, vision, etc. For example, food composition can contain vitamin A, C, D, E, B1, B2, B6, B12, nicotinic acid, biotin, folic acid, pantothenic acid, etc. In addition, food composition can contain minerals, such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr). In addition, food composition can also contain amino acids, such as lysine, tryptophan, cysteine, valine, etc.
[0160] In addition, the food composition may also contain food additives, such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder, advanced bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar color, etc.), color developers (sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (monosodium glutamate (MSG), etc.), sweeteners (glycine, cyclodextrin, saccharin, sodium, etc.), spices (vanillin, lactone, etc.), expanders (alum, D-potassium hydrogen tartrate, etc.), fortifiers, emulsifiers, thickeners (adhesives), film formers, gum bases, defoamers, solvents, enhancers, etc. Additives can be selected according to the type of food and used in appropriate amounts.
[0161] The composition according to one embodiment can be directly added, or it can be used in combination with other foods or food ingredients, and can be appropriately used according to a conventional method. The mixed amount of active ingredients can be appropriately determined according to the purpose of use (prevention, health care or treatment). Generally speaking, when producing food or beverage, the addition amount of the food composition of the present application can be less than 50 weight portions based on the total weight of food or beverage, specifically less than 20 weight portions. However, when taken for health and hygiene purposes, the content of the food composition can be less than the scope. In addition, due to the absence of safety issues, the amount of active ingredients can be higher than the scope.
[0162] The food composition can be used as a health drink composition, for example, and the health drink composition can also contain various flavoring agents or natural carbohydrates, the same as ordinary beverages. Natural carbohydrates can include monosaccharides, such as glucose and fructose; disaccharides, such as maltose and sucrose; polysaccharides, such as dextrin and cyclodextrin; sugar alcohols, such as xylitol, sorbitol, and erythritol. Sweeteners can be natural sweeteners, such as thaumatin or stevia extract; or synthetic sweeteners, such as saccharin or aspartame.
[0163] In addition, the health drink composition can also contain various nutrients, vitamins, minerals, flavoring agents, coloring agents, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohols or carbonating agents. In addition, the health drink composition can contain pulp for preparing natural fruit juice, fruit juice beverage or vegetable beverage. These ingredients can be used alone or in combination. The ratio of additives is not important, but is generally selected in the range of 0.01 to 0.1 weight parts per 100 weight parts of the health drink composition of the present application.
[0164] The food composition according to one embodiment may contain ingredients in various weight percentages as long as it can show the effect of preventing or alleviating inflammasome-mediated inflammatory diseases.
[0165] Feed composition, etc.
[0166] Another embodiment provides a feed additive (feed additive composition) for preventing and / or alleviating inflammasome-mediated diseases; and / or Gram-negative bacteria infection or diseases caused by Gram-negative bacteria, for protecting nerve cells and / or for regenerating (or generating) nerve cells, which comprises the above-mentioned compound.
[0167] Inflammasome-mediated diseases; and / or Gram-negative bacterial infections or diseases caused by Gram-negative bacteria are the same as above.
[0168] Some embodiments provide a feed comprising the above feed additive.
[0169] For feed, antibiotics or combination antibiotics can be prepared separately in the form of feed additives and mixed with the feed, or they can be added directly during the feed preparation process.
[0170] The compound, antibiotic or combination antibiotic in the feed may be in liquid or dry form, for example, in dry powder form. The content of the antibiotic may be 0.005 to 10 wt%, 0.05 to 10 wt%, 0.1 to 10 wt%, 0.005 to 5 wt%, 0.05 to 5 wt%, 0.1 to 5 wt%, 0.005 to 2 wt%, 0.05 to 2 wt% or 0.1 to 2 wt% based on the total weight of the feed, but is not limited thereto. In addition, in addition to the above-mentioned compound, antibiotic or combination antibiotic, the feed may also contain common additives that can improve the preservation of the feed.
[0171] In the present invention, the feed to which the compound, antibiotic or combination of antibiotics can be added can be selected from the group consisting of commercially available feed, grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils, starch, gourds, grain by-products, proteins, inorganic substances, oils, minerals, single-cell proteins, zooplankton, leftovers, etc., but is not limited thereto.
[0172] Some embodiments provide a food additive or drinking water additive comprising the above compound, antibiotic or combination antibiotic as an active ingredient. By mixing the compound, antibiotic or combination antibiotic in drinking water and providing it, the number of Gram-negative bacteria in drinking water can be reduced. The Gram-negative bacteria are the same as above.
[0173] Some embodiments provide a disinfectant comprising the above-mentioned compound, antibiotic or combination antibiotic as an active ingredient. Some embodiments provide a disinfection method, comprising the step of applying the above-mentioned compound, antibiotic or combination antibiotic to a subject in need of disinfection. Disinfectant is a general term for agents that prevent pathogen infection, and can be used for general life disinfectants, disinfectants for food and cooking places and facilities, and disinfection of poultry farms and fences, livestock carcasses, drinking water, garbage, egg trays, transport vehicles, tableware and other growth and development supplies.
[0174] Some embodiments provide a detergent comprising the above-mentioned compound, antibiotic or combination antibiotic as an active ingredient. Some embodiments provide a cleaning method, comprising applying the above-mentioned compound, antibiotic or combination antibiotic to a subject in need of cleaning. Since the antibiotic has an antibiotic effect against Gram-negative bacteria, it can be used to clean (clean) the skin surface or body part of an individual exposed to or likely to be exposed to Gram-negative bacteria. Gram-negative bacteria are the same as above.
[0175] Preparation method
[0176] In a final embodiment, a method for preparing the compound of Formula 1 is provided.
[0177] In one embodiment, the preparation method may include introducing phenylboronic acid or a derivative thereof (e.g., phenylboronic acid, Cas No. 98-80-6), 4-methylphenylboronic acid or p-tolylboronic acid (Cas No. 5720-05-8) or (4-methoxyphenyl)boronic acid (Cas No. 5720-07-0) into the compound of the following Chemical Formula 4 to prepare the compound of Chemical Formula 1.
[0178] [Chemical formula 4]
[0179]
[0180] In the compound of Chemical Formula 1, is an unsubstituted aryl group, and when R3 is a C1 alkyl (methyl) group, the step of preparing the compound of Chemical Formula 1 can be carried out by reacting phenylboronic acid (Cas No. 98-80-6), 4-methylphenylboronic acid or p-tolylboronic acid (Cas No. 5720-05-8) or (4-methoxyphenyl)boronic acid (Cas No. 5720-07-0) with the compound of Chemical Formula 4.
[0181] A person skilled in the art can prepare the compound by various methods according to the structure of Chemical Formula 1, and all of these methods should be considered within the scope of the present invention. That is, the compound of Chemical Formula 1 can be prepared within the scope of the present invention by any combination of several synthetic methods described herein or disclosed in the prior art. Therefore, the preparation method of the present invention is not limited to the following.
[0182] Beneficial Effects
[0183] The present application relates to: a compound of Chemical Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof; and its use in preventing, alleviating and / or treating diseases mediated by inflammasomes and / or Gram-negative bacteria infections or diseases caused by Gram-negative bacteria, which does not exhibit cytotoxicity and is therefore safe, and can effectively inhibit inflammasomes, thereby having excellent effects in preventing, alleviating and / or treating these diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0184] Figure 1 and Figure 2 The compounds of Examples 1-1 to 1-3 were treated at different concentrations (2 μM, 0.2 μM, 0.02 μM, 0.002 μM) on a culture medium cultured with Porphyromonas gingivalis, and the biofilm formation level (OD 590nm) and are shown in the figure. "NT" is the untreated group, "DPD" is the group in which the compound DPD is treated in the culture medium to culture Porphyromonas gingivalis, "CT" is the group in which PBS is treated in the culture medium instead of DPD to culture Porphyromonas gingivalis, and DPD+Example 1-1, DPD+Example 1-2, and DPD+Example 1-3 are the groups in which DPD is treated together with the example compounds.
[0185] Figures 3a to 3e The compounds of Examples 1-2 and the comparative example compounds were treated at different concentrations (2 μM, 0.2 μM, 0.02 μM, 0.002 μM) in a culture medium cultured with Porphyromonas gingivalis, and the biofilm formation level (OD 590nm ) and displayed in a diagram.
[0186] Figures 4a to 4d It is a graph showing the stability of the compounds of Examples 1-2 and the compounds of Comparative Examples in human plasma and rat plasma.
[0187] Figure 5a to Figure 5c The compounds of Examples 1-1 to 1-2 are respectively treated to the culture medium in which Porphyromonas gingivalis is cultured, and the expression levels of three gingipain proteins (lysine-gingipain (Kgp), arginine-gingipain A (RgpA), arginine-gingipain B (RgpB)) produced by Porphyromonas gingivalis are shown in the figure. These three gingipain proteins are the main virulence factors and proteolytic enzymes of Porphyromonas gingivalis. The 16SrRNA gene is used to normalize the expression of the gingipain gene. The "control" is an untreated group, and the "DPD" is a group in which the compound DPD is treated to the culture medium in which Porphyromonas gingivalis is cultured; DPD+Example 1-1 and DPD+Example 1-2 are groups in which hDPD is treated together with the compounds of the examples.
[0188] Figure 6 The compound of Example 1-2 was treated with mouse bone marrow-derived macrophages at various concentrations (0.5 μM to 16 μM), and the presence / absence of cytotoxicity was confirmed and displayed in a graph. "Control" is an untreated control group.
[0189] Figures 7a to 7d As a result of treating Gram-negative bacteria with the example compounds, it is shown that the biofilm of Escherichia coli was significantly inhibited compared with the positive control (CT) not treated with the example compounds. Figure 7a and 7b : Results for E. coli, Figure 7c : Results for Pseudomonas aeruginosa, Figure 7d : Results for Acinetobacter baumannii).
[0190] Figure 8 It was shown that as a result of treating Escherichia coli with the example compounds and the antibiotics, the minimum growth inhibitory concentration of the antibiotics was significantly lowered compared with the case of treating with the antibiotics alone.
[0191] Fig. 9 , 10 The figure is a schematic diagram showing that the compounds of the present application inhibit the biofilm formation of Gram-negative bacteria.
[0192] Fig.11 It was shown that Porphyromonas gingivalis infection induced inflammation in nerve cells, leading to cell damage, but treatment with the example compounds protected the nerve cells.
[0193] Fig.12 , 13 The graph shows that Porphyromonas gingivalis infection increases the gene expression of inflammatory factors in nerve cells, but the nerve inflammation is alleviated after treatment with the example compound.
[0194] Fig.14 The graph shows that the example compounds show no toxicity to neural cells.
[0195] Fig.15 This is a graph showing changes in plasma concentration over time when the Example compounds were intravenously injected into male rats to collect blood samples.
[0196] Fig.16 The figure shows the change of brain concentration over time when the example compound is intravenously injected into male rats to collect brain samples, indicating that the example compound reaches the brain through the blood and then passes through the blood-brain barrier, so it can act on the lesion site in the brain, i.e., the target site, to treat neurodegenerative diseases.
[0197] Fig.17 This figure shows that Example compounds were treated to mouse bone marrow-derived macrophages and changes in inflammatory cytokine (IL-1β) production in the macrophages were measured, showing that Example compounds inhibited inflammatory reactions induced in the macrophages.
[0198] Fig.18 This is a graph showing that the Example compounds do not exhibit cytotoxicity in mouse bone marrow-derived macrophages.
[0199] Fig.19 The graph shows that the example compounds do not exhibit cytotoxicity in a human monocytic cell line. DETAILED DESCRIPTION
[0200] Hereinafter, the present invention will be described in more detail by way of examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not intended to be limited to or by these examples.
[0201] Example 1. Preparation of compounds
[0202] Example 1-1. Preparation of 3-(diphenylmethylene)-2-methylisoindolin-1-one
[0203] The compound of Example 1-1 (3-(diphenylmethylene)-2-methylisoindolin-1-one (Cas No. 92172-54-8)) was prepared by performing the following steps.
[0204] Step 1: Preparation of Compound A
[0205] [Reaction Scheme 1]
[0206]
[0207] In 10mL THF (Cas No.109-99-9, Sigma Aldrich) containing Zn powder (Cas No.7440-66-6, Sigma Aldrich) (490mg, 7.50mmol), triisopropyl phosphite (P(i-PrO)3, Cas No.116-17-6, Sigma Aldrich) (2.7mL, 11.00mmol) was cooled to 0°C under argon (Cas No.7440-37-1, Sung Kwang SpecialtyGas). A solution of CBr4 (Cas No.558-13-4, TCI) (2.49g, 7.50mmol) in THF was slowly added to the P(i-PrO)3 solution, and the reaction mixture was stirred until the color changed to yellow. Then, a THF solution of N-methylphthalimide (Cas No.550-44-7, Sigma Aldrich) (806mg, 5.00mmol) was added thereto. The reaction mixture was stirred at room temperature for 12 hours.Add saturated NaHCO3 aqueous solution (CasNo.144-55-8, Samchun Chemicals) (2.5mL) and after quenching, separate each phase, extract the crude product from the aqueous layer with ether.The residue is dissolved in ether and filtered through a diatomaceous earth pad.The gained filtrate is concentrated by rotary evaporation, and purified by column chromatography (solution of 50% dichloromethane (DCM) in hexane), obtain compound A.
[0208] Step 2: Preparation of the compound of Example 1-1
[0209] Under argon atmosphere, compound A (158 mg, 0.5 mmol), Na2CO3 (212 mg, 2 mmol), Pd(OAC)2 (Cas No.3375-31-3, TCI) (22 mg, 0.1 mmol), PPh3 (Cas No.603-35-0, TCI) (52 mg, 0.2 mmol), H2O (2 mL) and THF (8 mL) prepared in step 1 were added to a Schlenk tube. Phenylboronic acid (Cas No.98-80-6, TCI) (1.2 mmol) was added to the mixture under stirring, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was extracted with DCM (Cas No.75-09-2, Sigma Aldrich) (10 mL), washed with brine, dried with MgSO4 (Cas No.10034-99-8, Samchun Chemicals), and filtered. The crude product was purified by flash chromatography on silica gel to obtain the compound of Example 1-1.
[0210] [Compound of Example 1-1]
[0211]
[0212] Example 1-2. Preparation of 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one
[0213] The compound of Example 1-2 (3-(di-p-tolylmethylene)-2-methylisoindolin-1-one) was prepared by performing the following steps.
[0214] Step 1: Preparation of Compound A
[0215] The preparation of compound A is the same as step 1 of Example 1-1.
[0216] Step 2: Preparation of the compound of Example 1-2
[0217] Under argon atmosphere, compound A (158 mg, 0.5 mmol), Na2CO3 (212 mg, 2 mmol), Pd(OAC)2 (22 mg, 0.1 mmol), PPh3 (52 mg, 0.2 mmol), H2O (2 mL) and THF (8 mL) prepared in step 1 were added to a Schlenk tube. 4-Methylphenylboronic acid or p-tolylboronic acid (Cas No.5720-05-8, TCI) (1.2 mmol) was added to the mixture under stirring, and the mixture was then stirred at room temperature for 24 hours. The reaction mixture was extracted with DCM (10 mL), washed with brine, dried and filtered with MgSO4. The crude product was purified by flash chromatography on silica gel to give the compound of Example 1-2.
[0218] [Compound of Example 1-2]
[0219]
[0220] Example 1-3. Preparation of 3-(bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one
[0221] The compound of Example 1-3 (3-(bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one) was prepared by performing the following steps.
[0222] Step 1: Preparation of Compound A
[0223] The preparation of compound A is the same as step 1 of Example 1-1.
[0224] Step 2: Preparation of the compounds of Examples 1-3
[0225] Under argon atmosphere, compound A (158 mg, 0.5 mmol), Na2CO3 (212 mg, 2 mmol), Pd(OAC)2 (22 mg, 0.1 mmol), PPh3 (52 mg, 0.2 mmol), H2O (2 mL) and THF (8 mL) prepared in step 1 were added to a Schlenk tube. 4-(Methoxyphenyl)boronic acid (Cas No. 5720-07-0, TCI) (1.2 mmol) was added to the mixture under stirring, and the mixture was then stirred at room temperature for 24 hours. The reaction mixture was extracted with DCM (10 mL), washed with brine, dried and filtered with MgSO4. The crude product was purified by flash chromatography on silica gel to give the compound of Example 1-3.
[0226] [Compounds of Examples 1-3]
[0227]
[0228] Preparation of the compound DPD of the comparative example
[0229] The compound DPD (4,5-dihydroxy-2,3-pentanedione, Cas No. 142937-55-1) used in the experimental examples described below was prepared by performing the following steps 1 to 5 (see Molecules. 2018 Oct; 23(10): 2545).
[0230] Step 1: 1-Propynylmagnesium bromide (0.5M in THF, 1.3 eq.) was slowly added to a 0°C solution of anhydrous (tert-butyldimethylsilyloxy)acetaldehyde (1.0 eq.) in THF. The mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated by rotary evaporation and then quenched by adding cooled saturated NH4Cl solution. The reaction mixture was then extracted with Et2O, washed with brine, dried over MgSO4 and filtered. A yellow oily substance 1 was obtained.
[0231] Step 2: The obtained substance 1 (1.0 equivalent) was dissolved in MeOH, Dowex 50WX8 100-200 mesh (100 mg / 1 mL) was added, and the mixture was stirred at room temperature for 12 hours. The substance 2 was obtained after filtration.
[0232] Step 3: Cyclohexanone dimethyl ketal (3.0 equivalents) and catalyst p-TSA were added to the obtained substance 2 (1.0 equivalents), and stirred at room temperature for 12 hours. The reaction solution was concentrated by rotary evaporation, dissolved with Et2O, washed with NaHCO3, dried with MgSO4, and filtered to obtain substance 3.
[0233] Step 4: Add the obtained substance 3 to a 1:1:1 CHCl3 / ACN / H2O solution, add NaIO4 (4.4 equivalents) and RuO2_H2O (2.5% mol), and stir at room temperature for 12 hours. The reaction solution is concentrated by rotary evaporation, extracted with DCM, and dried over MgSO4 to obtain substance 4.
[0234] Step 5: Add the obtained substance 4 to MeOH, add Dowex 50WX8 resin, and stir at room temperature for 12 hours. Filter the reaction mixture to obtain compound DPD.
[0235] Example 2. Inhibition of Porphyromonas gingivalis biofilm formation
[0236] The compounds of Examples 1-1 to 1-3 were confirmed to have inhibitory effects on biofilm formation of Porphyromonas gingivalis.
[0237] The compounds of Examples 1-1 to 1-3 were respectively treated on a culture medium (supplied by Korea Center for Oral Microbiology (KCOM) and used) in which Porphyromonas gingivalis was cultured, and the level of biofilm formation of Porphyromonas gingivalis was confirmed.
[0238] Use tweezers to place sterilized coverslips (circular, radius 12mm) at the bottom of each well of a cell culture plate (24-well plate), and add DPD (4,5-dihydroxy-2,3-pentanedione, Cas No.142937-55-1), a precursor of interbacterial signaling substance AI-2 (autoinducer-2), to a medium (BHI medium + supplement) in which Porphyromonas gingivalis is cultured at a concentration of 10 μM (the medium component BHI is brain heart infusion medium, and heme (10 μg / mL) and vitamin K (0.2 μg / mL) are used as supplements). It is known that the formation of bacterial biofilms increases as bacteria use DPD for quorum sensing. The example compounds (compounds of Examples 1-1 to 1-3) were diluted in a medium containing DPD, and prepared to have final concentrations of 0.002 μM, 0.02 μM, 0.2 μM and 2 μM, respectively.
[0239] The prepared culture medium was dispensed into a cell culture plate with a glass slide and inoculated with bacteria to a concentration of 2×10 8 Cells / mL. For the positive control (DPD) not treated with the example compounds, DPD was added to the culture medium (BHI culture medium + supplement), and then the same number of bacteria were inoculated. For the negative control (CT) not treated with the example compounds and DPD, an equal amount of PBS (phosphate buffered saline) was added to the culture medium (BHI culture medium + supplement) instead of DPD. The completed cell culture plate was maintained at 37°C, anaerobic conditions (10% H2, 10% CO2, 80% N2) for 48 hours to cultivate bacteria.
[0240] The biofilm formed by the bacteria cultured in each group on the glass slide was stained with 1% crystal violet solution for 15 minutes, then washed three times with PBS (phosphate buffered saline) solution and decolorized with acetone-alcohol (20:80, volume / volume). After adding the decolorization solution containing crystal violet to the microplate of each group in 200 μl increments, the absorbance (OD) was measured using an absorbance microplate reader (Epoch2, Bio-Tek, USA). 590nm ), and the results were compared and analyzed by group. Figure 1 and Figure 2 shown.
[0241] like Figure 1 and Figure 2As shown, no biofilm formation was observed in the culture medium (NT) not cultured with Porphyromonas gingivalis. In the culture medium (DPD) in which DPD was added to culture medium to culture Porphyromonas gingivalis, compared with the culture medium (CT) in which PBS was added to culture medium to culture Porphyromonas gingivalis, the biofilm formation of Porphyromonas gingivalis was significantly increased by quorum sensing. In the culture medium (DPD+Example 1-1, DPD+Implementation Case 1-2, DPD+Example 1-3) in which DPD and the example compound were added together to culture Porphyromonas gingivalis, it was confirmed that the biofilm formation of Porphyromonas gingivalis increased by DPD was inhibited in a concentration-dependent manner of the example compound.
[0242] Comparative experiment
[0243] In order to prove that the compounds of Examples 1-1 to 1-3 have better effects than the comparative compounds, the following experiment was conducted. As a comparative compound, the compound ((Z)-3-(bromo(phenyl)methylene)isobenzofuran-1(3H)-one) of <Example 1> of Korean Unexamined Patent Publication No. 10-2019-0130983A was used.
[0244] 1. Inhibitory effect on biofilm formation of Porphyromonas gingivalis
[0245] The inhibitory effects of the compounds of Examples 1-2 and the compounds of the comparative examples on the biofilm formation of Porphyromonas gingivalis were confirmed. The experimental process was carried out in the same manner as in Experimental Example 1. The experimental results are shown in FIG. Figures 3a to 3e shown.
[0246] from Figures 3a to 3e It can be seen that biofilm formation was not observed in the culture medium (NT) in which Porphyromonas gingivalis was not cultured. In the culture medium (DPD) in which DPD was added to the culture medium to culture Porphyromonas gingivalis, the biofilm formation of Porphyromonas gingivalis was significantly increased by quorum sensing compared with the culture medium (CT) in which PBS was added to the culture medium to culture Porphyromonas gingivalis. In the case of adding DPD and the example compound together to culture the culture medium (DPD+Comparative Example, DPD+Example 1-2), it was confirmed that the biofilm formation of Porphyromonas gingivalis increased by DPD was inhibited in a concentration-dependent manner of the compound. When the ability to inhibit the biofilm formation of Porphyromonas gingivalis at the same concentration was compared, it was confirmed that the compound of Example 1-2 had a better ability to inhibit biofilm formation than the comparative example compound.
[0247] 2. Plasma stability
[0248] The plasma stabilities of the compounds of Examples 1-2 and Comparative Examples in human plasma and rat plasma were compared.
[0249] 1) Sample preparation
[0250] The compounds of Examples 1-2 and Comparative Examples, and substances used as positive controls (eucatropine, loroprotinol) were dissolved in DMSO to prepare a stock solution with a concentration of 10 mM. The stock solution of each test substance was diluted to prepare 0.2 mM and 1 mM working solutions, and used in the test (the compounds of the Comparative Examples were prepared with 70% acetonitrile as solvent, and the compounds of Examples 1-2 were prepared with 50% acetonitrile as solvent).
[0251] 2) Test methods
[0252] The standard solutions of the positive control and the test substance were placed in test tubes containing two plasmas (human and rat) at concentrations of 1 μM and 5 μM, respectively, and then incubated at 37°C for a specified time (0, 30, 60, 120, 240 minutes) while shaking and mixing. At each time point, the mixture sample was distributed in 100 μl increments into a cell culture plate (96-well plate) containing 400 μl quencher to terminate the test, and after centrifugation (5000 × g, 10 minutes), 100 μl of the supernatant was taken out, mixed with 200 μl of ultrapure water, and then the solution was injected into the LC-MS / MS system to analyze the drug in each time zone. Thereby evaluating the plasma stability of the compounds of the comparative examples and Examples 1-2.
[0253] 3) Test results
[0254] Figure 4a (Compound of Example 1-2) and Figure 4b (Comparative Example Compound) shows the stability results in human plasma, Figure 4c (Compound of Example 1-2) and Figure 4d (Comparative Example Compound) shows the stability results in rat plasma.
[0255] from Figures 4a to 4d As can be seen, it was confirmed that for the compound of the comparative example, the amount of the compound remaining in the plasma decreased over time in human plasma and rat plasma ( Figure 4b and 4d ), but the compound of Example 1-2 remained stable in plasma ( Figure 4a and 4c ).
[0256] Example 3. Inhibition of gingipain expression in Porphyromonas gingivalis
[0257] The compounds of the examples were treated separately on the culture medium for culturing Porphyromonas gingivalis, and the expression levels of three gingipain proteins (lysine-gingipain (Kgp), arginine-gingipain A (RgpA), and arginine-gingipain B (RgpB)) produced by Porphyromonas gingivalis were confirmed. These three gingipain proteins are the main virulence factors and proteolytic enzymes of Porphyromonas gingivalis.
[0258] A medium containing 10 μM DPD (4,5-dihydroxy-2,3-pentanedione), which is a precursor of bacterial signaling substance (autoinducer-2), and a medium containing 2 μM of the example compound or not containing 2 μM of the example compound were respectively distributed into a cell culture plate (48-well plate), and then Porphyromonas gingivalis (2×10 8 The culture medium containing the bacteria was cultured under anaerobic conditions (10% H2, 10% CO2 and 80% N2) at 37°C for 48 hours.
[0259] After 48 hours, each culture medium was centrifuged at 13,000 rpm for 1 minute to remove the supernatant, and total RNA was extracted using the easy-BLUETM total RNA extraction kit (iNtRON Biotechnology, Sungnam, Korea) to synthesize cDNA, and then the expression of gingipain gene was confirmed by the real-time PCR method. cDNA was synthesized using CycleScript RT PreMix dN6 (Bioneer, Daejeon, Korea) and PCR amplified using Power SYBR TM Real-time (quantitative) reverse transcription-PCR (RT-qPCR) was performed using ELISA Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA).
[0260] The primer sequences used for amplification are shown in Table 1 The RT-qPCR amplification conditions were as follows: after enzyme activation at 95°C for 3 min, denaturation at 95°C for 10 s, primer annealing at 60°C for 30 s, repeated 40 times, and analyzed using the Bio-Rad CFX COnnect Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). To standardize the expression level of gingipain gene, 16S rRNA gene was used, and the gene expression level was calculated using the comparative Ct method (ΔΔCt), as shown in Figure 1 . Figures 5a to 5c shown.
[0261] [Table 1]
[0262]
[0263] like Figures 5a to 5c As shown, compared with the untreated group (control group), in the group treated with DPD, which is a precursor of AI-2 (DPD), Porphyromonas gingivalis recognized the quorum sensing signal molecule, and the expression levels of the three gingipain genes (rgpA, rgpB, kgp) were all increased compared with the control group. In the group treated with DPD and the example compound together (DPD+Example 1-1, DPD+Example 1-2), it was confirmed that the expression levels of the three gingipain genes increased by DPD were reduced.
[0264] Example 4. Cytotoxicity Evaluation
[0265] It was evaluated whether the example compounds exhibit cytotoxicity in mouse bone marrow-derived macrophages.
[0266] Bone marrow was isolated from the femur and tibia of 8-12 week old C57BL / 6J mice (available from Daehan Biolink) using a 26 g syringe, and the isolated bone marrow was differentiated into macrophages by culturing in a 150π cell culture plate in a medium containing IMDM medium + 30% L929 cell supernatant + 10% fetal bovine serum + 1% penicillin / streptomycin + 1% non-essential amino acids + 1% sodium pyruvate for 6 days and used in experiments.
[0267] The differentiated macrophages were cultured at 1×10 6 The concentration of cells / mL was seeded in 48-well plates in increments of 200 μl and stabilized for 12 hours at 37°C and 5% CO2. After removing the cultured cell supernatant, the compound of Example 2 was diluted in serum-free medium to concentrations of 0.5, 1, 2, 4, 8 and 16 μM, treated in increments of 200 μl, and cultured at 37°C and 5% CO2 for 24 hours.
[0268] Then, the culture cell supernatant was removed, treated with 200 μl of MTT solution at a concentration of 400 μg / mL, and then reacted at 7°C and 5% CO2 for 4 hours. Then, the reaction solution was removed, 200 μl of DMSO was added, and the absorbance was measured at 570 nm. At this time, the survival rate of the cells treated with the sample was calculated with the survival rate of the untreated cells as 100%, as shown in Figure 6 shown.
[0269] like Figure 6 As shown, it was confirmed that the compound of Example 1-2 did not show cytotoxicity in mouse bone marrow-derived macrophages at a concentration of 16 μM or less.
[0270] Example 5. Inhibition of biofilm formation of Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii
[0271] 1) Inhibition of Escherichia coli biofilm formation
[0272] The inhibitory effect of the compound of Example 1-2 on biofilm formation of Escherichia coli (KCTC 2571 (ATCC 8739); available from the Korean Collection of Oral Microorganisms (KCOM)) was confirmed.
[0273] Use tweezers to place sterilized cover slips (round, radius 12 mm) at the bottom of each well of a cell culture plate (24-well plate), and dilute the compounds of Examples 1-2 in a bacterial culture medium (LB medium) to a final concentration of 0.006 μg / mL, 0.06 μg / mL, 0.6 μg / mL, 1.2 μg / mL, 2.4 μg / mL, and 4.8 μg / mL.
[0274] Dispense the prepared culture medium into a cell culture plate with a coverslip and inoculate bacteria to a concentration of 2 × 10 7 Cells / mL. For the positive control (DPD) not treated with the compound, the same number of bacteria was inoculated in a medium (LB) without the above compound. For the negative control (CT) not treated with the compound and bacteria, only the culture medium (LB medium) was treated alone, and the completed cell culture plate was cultured under anaerobic conditions (10% H2, 10% CO2, 80% N2) at 37°C for 48 hours to culture the bacteria.
[0275] The biofilm formed by the bacteria cultured in each group on the glass slide was stained with 1% crystal violet solution for 15 minutes, then washed three times with PBS (phosphate buffered saline) solution and decolorized with acetone-alcohol (20:80, volume / volume). After the decolorization solution containing crystal violet was added to the 96-well microplate of each group in 200 μl increments, the absorbance (OD) was measured using an absorbance microplate reader (Epoch2, Bio-Tek, USA). 590nm ) and compared the biofilm formation levels. Figure 7a and 7b shown.
[0276] 2) Inhibitory effect on biofilm formation of Pseudomonas aeruginosa and Acinetobacter baumannii
[0277] The inhibitory effects of the compounds of Examples 1-2 on biofilm formation of Pseudomonas aeruginosa (available from the Korea Collection of Oral Microorganisms (KCOM)) and Acinetobacter baumannii (available from the Korea Culture Center of Microorganisms (KCCM)) were confirmed.
[0278] Use tweezers to place sterilized cover slips (round, radius 12 mm) at the bottom of each well of a cell culture plate (24-well plate), and dilute the compounds of Examples 1-2 in a culture medium containing bacteria (LB medium for Pseudomonas aeruginosa and NB medium for Acinetobacter baumannii) to a final concentration of 0.006 μg / mL, 0.06 μg / mL, and 0.6 μg / mL.
[0279] The prepared culture medium was distributed to the cell culture plate with the glass slide, and each bacteria was inoculated to a concentration of 2×10 7 Cells / mL. For the positive control (CT) not treated with the compound, the same number of bacteria were inoculated into the medium (LB or NB) without the above compound. For the negative control (NT) not treated with the compound and bacteria, only the medium (LB or NB) was treated alone. The completed cell culture plate was cultured under anaerobic conditions (10% H2, 10% CO2, 80% N2) at 37°C for 48 hours to culture the bacteria.
[0280] After the bacteria cultured in each group formed biofilms on glass slides, they were stained with 1% crystal violet solution for 15 minutes, washed three times with PBS (phosphate buffered saline) solution, and decolorized with acetone-alcohol (20:80, volume / volume). After the decolorization solution containing crystal violet was added to the 96-well microplate of each group in 200 μl increments, the absorbance (OD) was measured using an absorbance microplate reader (Epoch2, Bio-Tek, USA). 590nm ) and compared the biofilm formation levels. Figure 7c and 7d shown.
[0281] from Figures 7a to 7d As can be seen in the figure, it was confirmed that the biofilm of each bacteria (Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii) increased in the control group (CT) after 48 hours of culture, but in the group treated with the compound of Example 1-2, the biofilm formation was significantly inhibited in a concentration-dependent manner.
[0282] Example 6. Combined effects of antibiotics on Escherichia coli
[0283] After 100 μl of Escherichia coli culture medium (LB) was distributed into a cell culture plate (96-well plate), three antibiotics (imipenem (IPM, Sigma-Aldrich), meropenem (MEM, Sigma-Aldrich) and ceftriaxone (CRO, Sigma-Aldrich)) as a control group were administered at a final concentration of 0.0312 μmL to 32 μg / mL and serially diluted. In order to confirm whether the compound treatment of Example 1-2 can improve the efficacy of antibiotics, the experimental group mixed the compounds of Example 1-2 so that each antibiotic dilution contained 1 μg / mL. The final volume of the control group and the experimental group was 200 μl, and 1×10 5 coli, and then cultured at 37°C for 24-48 hours. After the culture was completed, the absorbance of each well (OD 600nm ), and compared the minimum growth inhibition concentration of the control group and the experimental group. The results are as follows Figure 8 shown.
[0284] from Figure 8 It can be seen that it was confirmed that the minimum growth inhibition concentration of three antibiotics (imipenem (IPM), meropenem (MEM) and ceftriaxone (CRO)) against Escherichia coli was reduced by 20% to 50% or more due to the presence of the example compounds. Through these results, it was confirmed that when the antibiotics were treated in combination with the example compounds of the present invention, the efficacy of the existing antibiotics was more improved than when the antibiotics were treated alone.
[0285] Example 7. Confirmation of inflammation inhibition and neuronal cell protection
[0286] Human neuroblastoma (SH-SY5Y cells) (available from the Korean Cell Line Bank) were cultured at 3 × 10 6 Cells / well were treated on a cell culture plate (6-well plate) and then cultured in an incubator at 37°C and 5% CO2 for 24 hours. The negative control was treated with only 3 mL of culture medium to the nerve cells attached to the cell culture plate, and the positive control was inoculated with Porphyromonas gingivalis (available from the Korean Center for Oral Microbiology (KCOM) and used) at an infection rate of 500 (MOI 500). In order to confirm the inflammatory relief effect of the example compounds on nerve cells, the experimental group was inoculated with the same number of Porphyromonas gingivalis, and then the compound of Example 1-2 was diluted and treated to 1 μg / mL (2.95 μM) on the culture medium.
[0287] The cell culture plates of each group were cultured in an incubator at 37°C and 5% CO2 for 24 hours. After the culture was completed, the morphological changes of the nerve cells in each group caused by the inflammatory response were confirmed by optical microscopy. Fig.11shown.
[0288] like Fig.11 As shown, in the nerve cells induced with inflammation by the stimulus of Porphyromonas gingivalis infection, cell damage such as cell morphology deformation was confirmed, but the nerve cells were protected by the treatment with the example compound.
[0289] Real-time PCR analysis
[0290] After the optical microscopy analysis, the supernatant was removed from the cell culture plate, and the remaining cells were analyzed by real-time PCR to analyze the levels of inflammatory cytokines in the neural cells of each group. Each group was treated with 1 mL of the reagent of the easy-BLUETM Total RNA Extraction Kit (iNtRON Biotechnology, Sungnam, Korea) to lyse the neural cells, and then total RNA was extracted from the lysate to synthesize cDNA. The real-time PCR method was used to confirm the expression of inflammatory cytokine genes. cDNA was synthesized using CycleScript RT PreMix dT20 (Bioneer, Daejeon, Korea) and PCR amplified using PowerSYBR TM Real-time (quantitative) reverse transcription-PCR (RT-qPCR) was performed using GenBank Accession No. 329664-0104 Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA).
[0291] The primer sequences used are shown in Table 2 below. The amplification conditions are as follows: enzyme activation at 95°C for 10 minutes, denaturation at 95°C for 10 seconds, primer annealing at 60°C for 30 seconds, repeated 40 times. The equipment used was the Bio-Rad CFX COnnect real-time PCR detection system (Bio-Rad, Hercules, CA, USA). Based on the expression level of the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase), the relative expression level of the inflammatory cytokine gene was calculated using the comparative Ct method (ΔΔCt). The results are shown in Table 2. Fig.12 shown.
[0292] [Table 2]
[0293]
[0294] ELISA analysis
[0295] For the supernatant samples separated from the cell culture plates, the amount of inflammatory cytokines secreted by the nerve cells was determined by ELISA technology. The capture antibody was coated in a 96-well plate at an appropriate concentration, incubated at 25°C for 24 hours, and then washed three times with washing buffer. Blocked with 300 μL of reagent dilution buffer at 25°C for 1 hour, and then washed three times with washing buffer. Then, 100 μL of each test sample and standard solution were treated and incubated for 2 hours. Two wells (repeated) were treated equally in all experimental groups, and washed three times with washing buffer during treatment. The detection antibody was treated with an appropriate concentration in increments of 100 μL, incubated for 2 hours, and then washed three times with washing buffer. After treatment with 100 μL of Streptavidin-HRP, the cells were incubated at 25°C in a dark place for 20 minutes. After the incubation was completed, 50 μL of stop solution was added and the absorbance (OD 450nm The result value is calculated by the average of the measured values, and the amount of inflammatory cytokines is calculated as Fig.13 shown.
[0296] from Fig.12 and Fig.13 It can be seen that after treatment with the example compounds, the gene expression and production of major inflammatory cytokines (IL-6, IL-8, TNF-α) in nerve cells were inhibited, thereby alleviating neuroinflammation.
[0297] Example 8. Cytotoxicity Evaluation
[0298] In order to confirm the safety of the example compounds to cells, the cytotoxicity to the neural cells used in the experiment was confirmed.
[0299] In order to evaluate whether the example compounds show toxicity to neural cells, human neuroblastoma (SH-SY5Y, 3×10 5 Cells / well) were distributed in a cell culture plate (48-well plate), treated with the compound of Example 1-2 at 2, 4, 8, 16, and 32 μM concentrations, and cultured in a 37°C, 5% CO2 incubator for 24 hours. After 24 hours, 50 μl of CCK-8 (Cell Counting Kit-8, Dojindo Molecular Technologies, Inc) solution was added to each well in an equal amount, and then cultured in a 37°C, 5% CO2 incubator for 1 to 3 hours. The absorbance (OD 450nm ) to evaluate cell activity. The cell survival rate of each experimental group was calculated with the cell survival rate of the control group not treated with the example compound as 100%. The results are shown in Figure 8 shown.
[0300] from Fig.14It can be seen that the Example compounds showed no cytotoxicity to neural cells at a concentration of 16 μM or less.
[0301] Example 9. Blood-brain barrier penetration test results
[0302] The compound of Example 1-2 was diluted to a concentration of 0.4 mg / mL in an excipient containing 10% DMSO + 65% PEG400 + 25% Sarin, and then injected intravenously (iv) at 5 mL / kg into male SD rats (Zhejiang Vital River Laboratory Animal Technology Co., Ltd), and then blood samples were collected at 60 μl increments at each time point (0.25h, 0.5h, 1h, 5h, 10h). The collected blood samples were centrifuged at 4°C, 8000rpm for 6 minutes, the supernatant was removed, and plasma samples were collected each time and stored at -50°C until analysis, and then used for analysis.
[0303] To analyze the concentration of substances in plasma, 20 μl of each of the hourly samples, standard samples, and QC (quality control) samples were taken and mixed with 60 μl of acetonitrile (ACN) (Cas No. 75-05-8) containing internal standard substances (tolbutamide (Cas No. 64-77-7) 200 ng / mL, propranolol (Cas No. 318-98-9) 50 ng / mL, and di(N,N'-diisopropylcarbodiimide) (Cas No. 693-13-0) 500 ng / mL). The mixture was vortexed for 1 minute and then centrifuged (13000 rpm, 4°C, 10 minutes), and the supernatant (50 μl) was separated and transferred to a 96-well plate containing purified water (150 μl) and shaken for 10 minutes. The final mixture (3 μl) was injected into the LC-MS / MS system to analyze the concentration of the compound in the plasma samples of each time zone. The results are shown in Figure 2. Fig.15 shown.
[0304] For brain samples, in order to obtain only samples in brain tissue, cardiac perfusion was performed, and then brain tissue was separated. Three times the weight (w / v) of saline solution was added to the separated brain tissue, and then ground together to prepare a homogenous sample solution. 20 μl of each brain sample, standard sample, and QC sample were mixed with 60 μl acetonitrile (ACN) (Cas No. 75-05-8) containing internal standard substances (tolbutamide (Cas No. 64-77-7) 200 ng / mL, propranolol (Cas No. 318-98-9) 50 ng / mL, di (N, N'-diisopropylcarbodiimide) (Cas No. 693) -13-0) 500 ng / mL), vortexed for 1 minute, centrifuged (13000 rpm, 4 ° C, 10 minutes), and the supernatant (50 μl) was transferred to a 96-well plate containing purified water (150 μl) and shaken for 10 minutes. The final mixture (3 μl) was injected into the LC-MS / MS system to analyze the concentration of the compound in the brain sample at each time zone. The concentration of the compound in the brain tissue was analyzed by converting the calculated sample solution concentration (ng / mL) to the concentration in the brain tissue (ng / g) reflecting the dilution factor. The results are shown in Fig.16 shown.
[0305] from Fig.15 and Fig.16 It can be seen that when the Example compound was intravenously injected (iv) into male SD rats at a dose of 2 mg / kg, the Example compound passed through the blood and then through the blood-brain barrier to reach the brain, and the Example compound remained in the brain for up to 10 hours after administration. Through the above results, it was confirmed that the Example compound acts on the brain lesions as the target site and can treat neurodegenerative diseases.
[0306] Example 10. Confirmation of anti-inflammatory effect of macrophages
[0307] In order to confirm the anti-inflammatory effect of the example compounds, mouse bone marrow-derived macrophages were differentiated, and changes in the production of inflammatory cytokines (IL-1β) in the macrophages after treatment with the compounds were measured.
[0308] Bone marrow was isolated from the femur and tibia of 8-12 week old C57BL / 6J mice (available from Daehan Biolink) using a 26 g syringe, and the isolated bone marrow was differentiated into macrophages by culturing in a 150π cell culture plate in a medium containing IMDM medium + 30% L929 cell supernatant + 10% fetal bovine serum + 1% penicillin / streptomycin + 1% non-essential amino acids + 1% sodium pyruvate for 6 days and used in the experiment.
[0309] The differentiated macrophages were cultured at 1×10 6Cells were seeded in 48-well plates at a concentration of 200 μl per well / mL and incubated at 37°C, 5% CO2 for 12 hours. The supernatant of the cultured cells was removed and 180 μl of LPS was added to serum-free medium at a concentration of 100 ng / mL and primed for 5 hours. The compounds of Example 1-2 were diluted to concentrations of 0.78125, 1.5625, 3.125, 6.25, 12.5, and 25 mg / mL and added in 200 μl increments (working concentrations: 0.078125, 0.15625, 0.3125, 0.625, 1.25, and 2.5 mg / mL). After 1 hour, ATP was treated as required (20 μl was added at a concentration of 10 mM and incubated for 30 minutes). After collecting the cultured cell supernatant samples, the amount of IL-1β was measured using ELISA technology. IL-1β is a representative inflammatory cytokine and is a cytokine released by the activity of NLRP3 inflammasome, such as Fig.17 shown.
[0310] from Fig.17 As can be seen in the results, it was confirmed that the compounds of Examples 1 and 2 inhibited the stimulus-increased IL-1β release in macrophages in a concentration-dependent manner. Therefore, the example compounds inhibited the inflammatory response induced in macrophages.
[0311] Example 11. Cytotoxicity evaluation
[0312] In order to confirm the safety of the example compounds on cells, it was evaluated whether the compounds exhibited cytotoxicity in mouse bone marrow-derived macrophages and a human monocytic cell line (THP-1) (available from the Korean Cell Line Bank (KCLB)).
[0313] For macrophages, differentiated macrophages were cultured at 1 × 10 6 The concentration of cells / mL was seeded in 48-well plates in increments of 200 μl and stabilized for 12 hours at 37°C and 5% CO2. After removing the supernatant of the cultured cells, the compounds of Examples 1-2 were diluted in serum-free medium to concentrations of 0.5, 1, 2, 4, 8, and 16 μM, treated in increments of 200 μl, and cultured for 24 hours at 37°C and 5% CO2.
[0314] Remove the supernatant of the cultured cells, add 200 μl of 400 μg / mL MTT solution, react for 4 hours at 7°C and 5% CO2, remove the reaction solution, add 200 μl DMSO, and measure the absorbance at 570 nm. At this time, the survival rate of the cells treated with the sample is calculated with the survival rate of the untreated cells as 100%. Fig.18 shown.
[0315] Human monocytic cell line (THP-1) was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone, Waltham, MA, USA) and 2.05 mM L-glutamate and antibiotics (100 units / mL penicillin, 100 μg / mL streptomycin) and then incubated at 1×10 5 The cells were seeded in a 96-well microtiter plate at a concentration of 1:1. The compound of Example 1-2 was diluted to a final concentration of 0.002 μM, 0.02 μM, 0.2 μM and 2 μM, and the cells in each well were treated and cultured for 24 hours.
[0316] Then, the cultured cells were treated with 10 μl of cell counting kit-8 (CCK-8, DOJINDO, Kumamoto, Japan) solution in each well, and then the absorbance at 450 nm was measured at each time zone (1 hour, 2 hours, 3 hours), and the results were obtained based on the absorbance data of the last time zone of 3 hours.
[0317] At this time, the cell viability of untreated cells was set as 100% as a reference, and the cell viability of cells treated with the sample was calculated and displayed in Fig.19 middle.
[0318] from Fig.18 and 19 As can be seen from the table, the compound of Example 1-2 showed no cytotoxicity in mouse bone marrow-derived macrophages at a concentration of 16 μM or less, and showed no cytotoxicity in a human monocytic cell line (THP-1) at any concentration.
[0319] Example 12. Evaluation of drug safety by rat micronucleus test
[0320] In order to confirm the safety of the example compounds in experimental animals, namely rats (purchased from ORIENTBIO INC., Republic of Korea), SD (Sprague-Dawley) rat bone marrow cells were used to observe general symptoms, body weight changes, and the presence of micronucleus induction (genotoxicity) after substance administration.
[0321] The hair at the administration site (subcutaneous) of SD rats was removed, and the administration concentration of the example compound was set to low dose (500 mg / kg / day), medium dose (1000 mg / kg / day), and high dose (2000 mg / kg / day), and the compound was subcutaneously administered to the left and right cervix of the test system (10 mL / kg / day each), and the compound was subcutaneously administered to the left and right cervix of the test system in separate doses (10 mL / kg / day each). During the administration period, the general symptoms such as appearance, behavior, excretion, etc. of each individual were observed twice a day (before and immediately after administration) and once a day at other times. The results are shown in Table 3 below.
[0322] In addition, body weight was measured at the start of administration and on the day of bone marrow collection to confirm whether there was a change due to administration of the substance, and the results are shown in Table 4 below.
[0323] After the second administration of the test substance for 24 hours, the femur was removed from each group to collect bone marrow cells. 0.5mL 10% neutral formalin was added to the bone marrow cell suspension, fixed for 5 minutes, and centrifuged for 5 minutes (4°C, 1,000rpm, Micro17TR, Hanil Science Industrial, Republic of Korea) to remove the supernatant. Then, 0.3mL 10% neutral formalin was added to the precipitated bone marrow cells, suspended, filtered through the cell strain, and transferred to a storage tube. The fixed bone marrow cell suspension was dropped onto a coverslip and then covered with a slide coated with 20μL 0.05% acridine orange to prepare an observation slide. The observation slide was observed under a microscope (600 times magnification, BX51, Olympus, Japan). 4,000 polychromatic erythrocytes (PCE) were observed for each individual, and the incidence rate of micronucleated polychromatic erythrocytes (MNPCE) and polychromatic erythrocytes (MNPCE / PCE) was calculated for each individual. The results are shown in Table 3 below.
[0324] In addition, it can be confirmed from the observation results that the ratio of polychromatic erythrocytes to total erythrocytes in the test substance group (treated with the compound of Example 1-2) was 20% or more of that in the negative control. As an indicator of myeloid cell proliferation inhibition, 500 total erythrocytes per individual were observed, and the ratio of polychromatic erythrocytes to total erythrocytes (PCE / (PCE+NCE)) was calculated. The results are shown in Table 5 below. As a positive control, cyclophosphamide (Cas No: 50-18-0) was administered at a dose of 20 mg / kg / day.
[0325] [Table 3]
[0326] Table 3 Changes of clinical indicators in rats after substance administration
[0327]
[0328] SC: Subcutaneous
[0329] PO: oral
[0330] CPA: Cyclophosphamide
[0331] No obvious abnormalities
[0332] ∧Administer the positive control substance once 24 hours before sampling
[0333] [Table 4]
[0334] Table 4 Body weight changes of rats after substance administration
[0335]
[0336] SC: Subcutaneous
[0337] PO: oral
[0338] SD: Standard deviation
[0339] CPA: Cyclophosphamide
[0340] ∧: Administer the positive control substance once 24 hours before sampling
[0341] [Table 5]
[0342] Table 5 Micronucleus frequency induced by test substances in rats
[0343]
[0344] SC: Subcutaneous
[0345] PO: oral
[0346] MNPCE: Mild blue polychromatic erythrocyte
[0347] PCE: Polychromatic Erythrocytes
[0348] NCE: Colorless red blood cells
[0349] SD no standard deviation
[0350] CPA: Cyclophosphamide
[0351] Significant differences from negative control by Mann-Whitney U test: p<0.001
[0352] As can be seen from the experimental results in Table 3, during the observation period, at all doses of the compound of Example 1-2, no abnormal clinical signs of the rats were observed in the test substance groups (groups to which the compound of Example 1-2 was administered).
[0353] In addition, it can be seen from Table 4 that at all doses of the compound of Examples 1-2, the test substance groups did not show statistically significant changes in body weight compared with the negative control.
[0354] In addition, it can be seen from Table 5 that at all doses of the compound of Example 1-2, the frequency of occurrence of micronucleated polychromatic erythrocytes in polychromatic erythrocytes (MNPCE / PCE) did not show a statistically significant difference compared with the negative control in the test substance group, and the ratio of polychromatic erythrocytes to total erythrocytes [PCE / (PCE+NCE)] did not show a statistically significant difference compared with the negative control. On the other hand, although no statistically significant difference was confirmed in the ratio of polychromatic erythrocytes compared with the negative control, it was confirmed that the frequency of occurrence of micronucleated polychromatic erythrocytes in polychromatic erythrocytes was statistically significantly increased compared with the negative control (p<0.01).
[0355] From the above results, it was confirmed that the Example compounds did not induce micronuclei in rat bone marrow cells and were therefore safe.
[0356] From the above description, those skilled in the art to which the present application belongs will be able to understand that the present application can be implemented in other specific forms without changing its technical spirit or basic features. In this regard, it should be understood that the above embodiments are illustrative and not restrictive in all respects. The scope of the present application should be understood as all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than detailed description are included within the scope of the present application.
Claims
1. A pharmaceutical composition for preventing or treating an inflammasome-mediated disease, comprising at least one selected from the group consisting of a compound of the following chemical formula 1, an isomer thereof, and a pharmaceutically acceptable salt thereof as an active ingredient: [Chemical formula 1] in, In Chemical Formula 1, is substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C 3-7 a cycloalkenyl group, a substituted or unsubstituted C 3-7 Heterocycloalkyl, substituted or unsubstituted C containing at least one double bond and containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkenyl, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 At least one substituent selected from the group consisting of linear or branched alkoxy groups, The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R3 is substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkyl, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 Heteroaryl substitution, The substituted alkoxy, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R1 and R2 are each independently hydrogen, halogen, substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing at least one heteroatom selected from the group consisting of N, O and S 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl substituted, and The substituted alkoxy, substituted aryl, or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
2. The pharmaceutical composition according to claim 1, wherein is substituted or unsubstituted C 6-10 Aryl, The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 is substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups, and The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
3. The pharmaceutical composition according to claim 1, wherein R3 is substituted or unsubstituted C 1-10 Straight chain or branched chain alkyl.
4. The pharmaceutical composition according to claim 1, wherein R1 and R2 are each independently substituted or unsubstituted C 6-10 Aryl, and The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
5. The pharmaceutical composition according to claim 1, wherein The compound of Chemical Formula 1 is selected from the group consisting of: 3-(Diphenylmethylene)-2-methylisoindolin-1-one, 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
6. The pharmaceutical composition according to claim 1, wherein The inflammasome-mediated disease is at least one selected from the group consisting of periodontal disease, neurodegenerative disease and inflammatory disease.
7. The pharmaceutical composition according to claim 6, wherein The periodontal disease is at least one selected from the group consisting of periodontitis and gingivitis.
8. The pharmaceutical composition according to claim 6, wherein The neurodegenerative disease is at least one selected from the group consisting of dementia, Parkinson's disease, hand tremor, chorea, proximal lateral sclerosis, multiple sclerosis, Huntington's disease, motor neuron disease, spinal muscular atrophy, Creutzfeldt-Jakob disease, Pick's disease, prion disease and spinocerebellar ataxia.
9. The pharmaceutical composition according to claim 6, wherein The inflammatory disease is at least one selected from the group consisting of: At least one metabolic disease selected from the group consisting of obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH); At least one autoinflammatory disease selected from the group consisting of Weed syndrome (MWS), latent autoimmune diabetes in adults (LADA), familial cold autoinflammatory syndrome (FCAS), cryopyrin-associated periodic syndrome (CAPS), neonatal-onset multisystem inflammatory syndrome (NOMID), chronic infantile neurocutaneous-articular (CINCA) syndrome, familial Mediterranean fever (FMF), juvenile arthritis, juvenile rheumatoid arthritis and gout; At least one autoimmune disease selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), atopic dermatitis (AD) and psoriasis; At least one disease selected from the group consisting of septic shock, inflammatory bowel disease, osteoarthritis, hyperimmunoglobulin D syndrome and pyropyrin-associated periodic syndrome.
10. A food composition for preventing or alleviating an inflammasome-mediated disease, comprising at least one selected from the group consisting of the compound of Chemical Formula 1 according to any one of claims 1 to 5, its isomers and pharmaceutically acceptable salts thereof as an active ingredient.
11. A feed composition for preventing or alleviating an inflammasome-mediated disease, comprising at least one selected from the group consisting of the compound of Chemical Formula 1 according to any one of claims 1 to 5, its isomers and pharmaceutically acceptable salts thereof as an active ingredient.
12. A pharmaceutical composition for preventing or treating a disease caused by Gram-negative bacteria or Gram-negative bacteria, comprising at least one selected from the group consisting of a compound of the following Chemical Formula 1, its isomers and pharmaceutically acceptable salts thereof as an active ingredient: [Chemical formula 1] in, In Chemical Formula 1, is substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C 3-7 a cycloalkenyl group, a substituted or unsubstituted C 3-7 Heterocycloalkyl, substituted or unsubstituted C containing at least one double bond and containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkenyl, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 At least one substituent selected from the group consisting of linear or branched alkoxy groups, The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R3 is substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkyl, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 Heteroaryl substitution, The substituted alkoxy, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R1 and R2 are each independently hydrogen, halogen, substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl substituted, and The substituted alkoxy, substituted aryl, or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl, C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
13. The pharmaceutical composition according to claim 12, wherein is substituted or unsubstituted C 6-10 Aryl, The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 is substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups, and The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
14. The pharmaceutical composition according to claim 12, wherein R3 is substituted or unsubstituted C 1-10 Straight chain or branched chain alkyl.
15. The pharmaceutical composition according to claim 12, wherein R1 and R2 are each independently substituted or unsubstituted C 6-10 Aryl, and The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
16. The pharmaceutical composition according to claim 12, wherein The compound of Chemical Formula 1 is selected from the group consisting of: 3-(Diphenylmethylene)-2-methylisoindolin-1-one, 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
17. The pharmaceutical composition according to claim 12, wherein The infection by Gram-negative bacteria or the disease caused by Gram-negative bacteria is at least one selected from the group consisting of enteritis, Crohn's disease, ulcerative colitis, bacillary dysentery, urinary tract infection, skin infection, bacteremia, sepsis, skin infection, bedsore, pneumonia, endocarditis, meningitis, otitis externa, otitis media, periodontitis, gingivitis, keratitis, osteomyelitis, peritonitis and cystic fibrosis.
18. A food composition for preventing or alleviating infection by Gram-negative bacteria or diseases caused by Gram-negative bacteria, comprising at least one selected from the group consisting of the compound of Chemical Formula 1 according to any one of claims 12 to 17, its isomers and pharmaceutically acceptable salts thereof as an active ingredient.
19. A feed composition for preventing or alleviating infection by Gram-negative bacteria or diseases caused by Gram-negative bacteria, comprising at least one selected from the group consisting of the compound of Chemical Formula 1 according to any one of claims 12 to 17, its isomers and pharmaceutically acceptable salts thereof as an active ingredient.
20. An antibiotic comprising at least one selected from the group consisting of a compound of the following Chemical Formula 1, an isomer thereof, and a pharmaceutically acceptable salt thereof as an active ingredient: [Chemical formula 1] in, In Chemical Formula 1, is substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C 3-7 a cycloalkenyl group, a substituted or unsubstituted C 3-7 Heterocycloalkyl, substituted or unsubstituted C containing at least one double bond and containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkenyl, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 At least one substituent selected from the group consisting of linear or branched alkoxy groups, The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R3 is substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C containing at least one heteroatom selected from the group consisting of N, O and S 3-7 Heterocycloalkyl, substituted or unsubstituted C 6-10 an aryl group and a substituted or unsubstituted C 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 aryl, or a substituted or unsubstituted C containing one or more heteroatoms selected from the group consisting of N, O and S 5-10 Heteroaryl substitution, The substituted alkoxy, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of linear or branched alkoxy groups, R1 and R2 are each independently hydrogen, halogen, substituted or unsubstituted C 1-10 Straight chain or branched alkyl, substituted or unsubstituted C 1-10 Straight chain or branched alkoxy, substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl, The substituted alkyl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 At least one substituent selected from the group consisting of a linear or branched alkoxy group; or a substituted or unsubstituted C 6-10 an aryl group, or a substituted or unsubstituted C 5-10 Heteroaryl substituted, and The substituted alkoxy, substituted aryl, or substituted heteroaryl may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
21. The antibiotic according to claim 20, wherein is substituted or unsubstituted C 6-10 Aryl, The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, substituted or unsubstituted C 1-10 Straight chain or branched alkyl and substituted or unsubstituted C 1-10 is substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups, and The substituted alkyl or substituted alkoxy may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
22. The antibiotic according to claim 20, wherein R3 is substituted or unsubstituted C 1-10 Straight chain or branched chain alkyl.
23. The antibiotic according to claim 20, wherein R1 and R2 are each independently substituted or unsubstituted C 6-10 Aryl, and The substituted aryl group may be selected from hydroxy, halogen, cyano, nitro, amino, C 1-5 Straight or branched alkyl and C 1-5 The alkoxy group may be substituted with at least one substituent selected from the group consisting of linear or branched alkoxy groups.
24. The antibiotic according to claim 20, wherein The compound of Chemical Formula 1 is selected from the group consisting of: 3-(Diphenylmethylene)-2-methylisoindolin-1-one, 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
25. The antibiotic according to claim 20, which has antibiotic activity against Gram-negative bacteria.
26. The antibiotic according to claim 20, wherein The Gram-negative bacteria is at least one selected from the group consisting of Escherichia sp., Pseudomonas sp., Acinetobacter sp., Enterobacter sp., Klebsiella sp., Porphyromonas sp., Fusobacteria sp. and Tannerella sp.
27. A combination antibiotic comprising: The antibiotic according to claim 20; as well as At least one second antibiotic selected from the group consisting of β-lactam antibiotics, bacterial cell membrane permeability inhibitors, bacterial ribosome inhibitors, bacterial nucleic acid synthesis inhibitors and bacterial folate synthesis inhibitors.
28. A feed additive comprising the antibiotic according to claim 20.
29. A disinfectant comprising the antibiotic according to claim 20.
30. A cleaning agent comprising the antibiotic according to claim 20.
31. A compound having the following chemical formula 1A, an isomer thereof, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1A] in, In Chemical Formula 1A, R1, R2 and R3 are as defined in claim 1, and The compound of Chemical Formula 1A does not include the following compounds: 3-(Diphenylmethylene)-2-methylisoindolin-1-one.
32. The compound according to claim 31, its isomer or pharmaceutically acceptable salt thereof, wherein: The compound of Formula 1A is selected from the group consisting of: 3-(di-p-tolylmethylene)-2-methylisoindolin-1-one, and 3-(Bis(4-methoxyphenyl)methylene)-2-methylisoindolin-1-one.
33. A method for preparing a compound according to claim 31 or 32, the method comprising: Phenylboronic acid (Cas No. 98-80-6), 4-methylphenylboronic acid (Cas No. 5720-05-8) or (4-methoxyphenyl)boronic acid (Cas No. 5720-07-0) is introduced into the compound of the following Chemical Formula 4: [Chemical formula 4]
Citation Information
Cited By
Application of vanillin in preparation of klebsiella pneumoniae capsule inhibitor
CN122163585A
